WO2016027837A1 - 経口美容剤 - Google Patents
経口美容剤 Download PDFInfo
- Publication number
- WO2016027837A1 WO2016027837A1 PCT/JP2015/073272 JP2015073272W WO2016027837A1 WO 2016027837 A1 WO2016027837 A1 WO 2016027837A1 JP 2015073272 W JP2015073272 W JP 2015073272W WO 2016027837 A1 WO2016027837 A1 WO 2016027837A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hesperidin
- glycosyl
- hesperetin
- glycosyl hesperetin
- reducing agent
- Prior art date
Links
- 230000003796 beauty Effects 0.000 title claims abstract description 65
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims abstract description 416
- 235000010209 hesperetin Nutrition 0.000 claims abstract description 266
- 229960001587 hesperetin Drugs 0.000 claims abstract description 251
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 claims abstract description 250
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 claims abstract description 250
- -1 glycosyl hesperetin Chemical compound 0.000 claims abstract description 225
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 51
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 166
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 165
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 165
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 165
- 229940025878 hesperidin Drugs 0.000 claims description 165
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 165
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 114
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 claims description 98
- 239000000203 mixture Substances 0.000 claims description 76
- 239000007787 solid Substances 0.000 claims description 40
- IMMBLRJLSYJQIZ-UNQGIHKMSA-N (2S)-7-[3,4-dihydroxy-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxymethyl]oxan-2-yl]oxy-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydrochromen-4-one Chemical compound COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(OC3OC(COC4OC(C)C(O)C(O)C4O)C(OC4OC(CO)C(O)C(O)C4O)C(O)C3O)cc2O1 IMMBLRJLSYJQIZ-UNQGIHKMSA-N 0.000 claims description 39
- 239000002537 cosmetic Substances 0.000 claims description 34
- 239000007864 aqueous solution Substances 0.000 claims description 31
- 238000002360 preparation method Methods 0.000 claims description 23
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 19
- 239000011591 potassium Substances 0.000 claims description 19
- 229910052700 potassium Inorganic materials 0.000 claims description 19
- 239000011777 magnesium Substances 0.000 claims description 18
- 229910052749 magnesium Inorganic materials 0.000 claims description 18
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 17
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 16
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 16
- 239000011575 calcium Substances 0.000 claims description 16
- 229910052791 calcium Inorganic materials 0.000 claims description 16
- 239000011734 sodium Substances 0.000 claims description 16
- 229910052708 sodium Inorganic materials 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 14
- 238000002835 absorbance Methods 0.000 claims description 11
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 6
- 239000006072 paste Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- UAJRSHJHFRVGMG-UHFFFAOYSA-N 1-ethenyl-4-methoxybenzene Chemical compound COC1=CC=C(C=C)C=C1 UAJRSHJHFRVGMG-UHFFFAOYSA-N 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 235000015110 jellies Nutrition 0.000 claims description 3
- 239000008274 jelly Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 claims 1
- 230000036548 skin texture Effects 0.000 abstract description 8
- 239000000047 product Substances 0.000 description 183
- 239000003638 chemical reducing agent Substances 0.000 description 165
- 238000012360 testing method Methods 0.000 description 129
- 210000003491 skin Anatomy 0.000 description 114
- 230000002829 reductive effect Effects 0.000 description 91
- 235000019640 taste Nutrition 0.000 description 86
- 238000004040 coloring Methods 0.000 description 69
- 239000000243 solution Substances 0.000 description 67
- 238000006911 enzymatic reaction Methods 0.000 description 48
- 238000011156 evaluation Methods 0.000 description 46
- 235000013305 food Nutrition 0.000 description 42
- 238000004519 manufacturing process Methods 0.000 description 38
- 238000000034 method Methods 0.000 description 38
- 239000000126 substance Substances 0.000 description 38
- 230000000694 effects Effects 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- 206010015150 Erythema Diseases 0.000 description 31
- 238000004383 yellowing Methods 0.000 description 31
- 208000003251 Pruritus Diseases 0.000 description 26
- 231100000321 erythema Toxicity 0.000 description 26
- 230000007794 irritation Effects 0.000 description 26
- 239000002994 raw material Substances 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 108700023372 Glycosyltransferases Proteins 0.000 description 25
- 230000036541 health Effects 0.000 description 25
- 229920001353 Dextrin Polymers 0.000 description 22
- 239000004375 Dextrin Substances 0.000 description 22
- 102000004190 Enzymes Human genes 0.000 description 22
- 108090000790 Enzymes Proteins 0.000 description 22
- 102000051366 Glycosyltransferases Human genes 0.000 description 22
- 241000282412 Homo Species 0.000 description 22
- 229920002472 Starch Polymers 0.000 description 22
- 235000019425 dextrin Nutrition 0.000 description 22
- 229940088598 enzyme Drugs 0.000 description 22
- 239000008107 starch Substances 0.000 description 22
- 235000019698 starch Nutrition 0.000 description 22
- 230000009471 action Effects 0.000 description 21
- 235000013376 functional food Nutrition 0.000 description 20
- 239000003463 adsorbent Substances 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 125000003147 glycosyl group Chemical group 0.000 description 18
- 229940091250 magnesium supplement Drugs 0.000 description 17
- 238000005259 measurement Methods 0.000 description 17
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical group C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 230000001603 reducing effect Effects 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 235000013402 health food Nutrition 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 230000008859 change Effects 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 230000037406 food intake Effects 0.000 description 12
- 230000036961 partial effect Effects 0.000 description 12
- 239000012086 standard solution Substances 0.000 description 12
- 206010013911 Dysgeusia Diseases 0.000 description 11
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 11
- 150000008040 ionic compounds Chemical class 0.000 description 11
- 235000016709 nutrition Nutrition 0.000 description 11
- 108010025880 Cyclomaltodextrin glucanotransferase Proteins 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 10
- 150000001720 carbohydrates Chemical class 0.000 description 10
- 239000007857 degradation product Substances 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
- 229910052751 metal Inorganic materials 0.000 description 9
- 235000010262 sodium metabisulphite Nutrition 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- 206010013786 Dry skin Diseases 0.000 description 8
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 8
- 102100022624 Glucoamylase Human genes 0.000 description 8
- 108010044879 alpha-L-rhamnosidase Proteins 0.000 description 8
- 235000019658 bitter taste Nutrition 0.000 description 8
- 229920001429 chelating resin Polymers 0.000 description 8
- 230000037336 dry skin Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000001953 sensory effect Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 230000036962 time dependent Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 244000269722 Thea sinensis Species 0.000 description 6
- 238000011088 calibration curve Methods 0.000 description 6
- 235000020971 citrus fruits Nutrition 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000000007 visual effect Effects 0.000 description 6
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 5
- 241000234435 Lilium Species 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 239000008103 glucose Chemical group 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 229910021642 ultra pure water Inorganic materials 0.000 description 5
- 239000012498 ultrapure water Substances 0.000 description 5
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 4
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 229920002245 Dextrose equivalent Polymers 0.000 description 4
- 235000016623 Fragaria vesca Nutrition 0.000 description 4
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 4
- 108090000637 alpha-Amylases Proteins 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 4
- 235000001368 chlorogenic acid Nutrition 0.000 description 4
- GZSOSUNBTXMUFQ-YFAPSIMESA-N diosmin Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 GZSOSUNBTXMUFQ-YFAPSIMESA-N 0.000 description 4
- 229960004352 diosmin Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 108010030923 hesperidinase Proteins 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000419 plant extract Substances 0.000 description 4
- 235000010265 sodium sulphite Nutrition 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 235000013616 tea Nutrition 0.000 description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241001672694 Citrus reticulata Species 0.000 description 3
- 240000007154 Coffea arabica Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 240000008620 Fagopyrum esculentum Species 0.000 description 3
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 3
- 240000009088 Fragaria x ananassa Species 0.000 description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 241000235070 Saccharomyces Species 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 102000004139 alpha-Amylases Human genes 0.000 description 3
- 108010028144 alpha-Glucosidases Proteins 0.000 description 3
- 229940024171 alpha-amylase Drugs 0.000 description 3
- 108010019077 beta-Amylase Proteins 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 3
- 229940074393 chlorogenic acid Drugs 0.000 description 3
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 3
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000016213 coffee Nutrition 0.000 description 3
- 235000013353 coffee beverage Nutrition 0.000 description 3
- 231100000676 disease causative agent Toxicity 0.000 description 3
- 210000000624 ear auricle Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- XPFVYQJUAUNWIW-UHFFFAOYSA-N furfuryl alcohol Chemical compound OCC1=CC=CO1 XPFVYQJUAUNWIW-UHFFFAOYSA-N 0.000 description 3
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 3
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 229940010454 licorice Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 description 3
- 235000014214 soft drink Nutrition 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 229920003002 synthetic resin Polymers 0.000 description 3
- 239000000057 synthetic resin Substances 0.000 description 3
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 2
- RYYXDZDBXNUPOG-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine;dihydrochloride Chemical compound Cl.Cl.C1C(N)CCC2=C1SC(N)=N2 RYYXDZDBXNUPOG-UHFFFAOYSA-N 0.000 description 2
- UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 description 2
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
- FCSPXCQJNMMNMO-UHFFFAOYSA-N 7-hydroxy-4,6-dimethyl-3h-2-benzofuran-1-one Chemical compound CC1=CC(C)=C(O)C2=C1COC2=O FCSPXCQJNMMNMO-UHFFFAOYSA-N 0.000 description 2
- 244000235603 Acacia catechu Species 0.000 description 2
- 235000006020 Acacia catechu Nutrition 0.000 description 2
- 239000009405 Ashwagandha Substances 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 241000228245 Aspergillus niger Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000555281 Brevibacillus Species 0.000 description 2
- 241000186146 Brevibacterium Species 0.000 description 2
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 2
- 235000011511 Diospyros Nutrition 0.000 description 2
- 244000055850 Diospyros virginiana Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 2
- 240000001238 Gaultheria procumbens Species 0.000 description 2
- 241000626621 Geobacillus Species 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- 244000194101 Ginkgo biloba Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 241000208680 Hamamelis mollis Species 0.000 description 2
- 244000020551 Helianthus annuus Species 0.000 description 2
- 235000003222 Helianthus annuus Nutrition 0.000 description 2
- 235000013719 Houttuynia cordata Nutrition 0.000 description 2
- 240000000691 Houttuynia cordata Species 0.000 description 2
- 244000017020 Ipomoea batatas Species 0.000 description 2
- 235000002678 Ipomoea batatas Nutrition 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical group C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- 241000408747 Lepomis gibbosus Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 244000288157 Passiflora edulis Species 0.000 description 2
- 235000000370 Passiflora edulis Nutrition 0.000 description 2
- 241000237509 Patinopecten sp. Species 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 241000205160 Pyrococcus Species 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- OVVGHDNPYGTYIT-VHBGUFLRSA-N Robinobiose Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O1 OVVGHDNPYGTYIT-VHBGUFLRSA-N 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 241000698291 Rugosa Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 235000009470 Theobroma cacao Nutrition 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- 235000017606 Vaccinium vitis idaea Nutrition 0.000 description 2
- 244000077923 Vaccinium vitis idaea Species 0.000 description 2
- 235000001978 Withania somnifera Nutrition 0.000 description 2
- 240000004482 Withania somnifera Species 0.000 description 2
- 239000001560 acacia catechu Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 235000010208 anthocyanin Nutrition 0.000 description 2
- 229930002877 anthocyanin Natural products 0.000 description 2
- 239000004410 anthocyanin Substances 0.000 description 2
- 150000004636 anthocyanins Chemical class 0.000 description 2
- 235000019606 astringent taste Nutrition 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 235000004883 caffeic acid Nutrition 0.000 description 2
- 229940074360 caffeic acid Drugs 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 description 2
- 235000019126 equol Nutrition 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 229940108690 glucosyl hesperidin Drugs 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- 150000002387 hesperetin Chemical class 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 229960003998 ifenprodil Drugs 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 description 2
- 238000009616 inductively coupled plasma Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 2
- 235000010263 potassium metabisulphite Nutrition 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 235000020236 pumpkin seed Nutrition 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 235000021283 resveratrol Nutrition 0.000 description 2
- 229940016667 resveratrol Drugs 0.000 description 2
- OVVGHDNPYGTYIT-BNXXONSGSA-N rutinose Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 OVVGHDNPYGTYIT-BNXXONSGSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 235000020637 scallop Nutrition 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 230000036620 skin dryness Effects 0.000 description 2
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 2
- 235000010269 sulphur dioxide Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000005918 transglycosylation reaction Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000020234 walnut Nutrition 0.000 description 2
- DBRXOUCRJQVYJQ-CKNDUULBSA-N withaferin A Chemical compound C([C@@H]1[C@H]([C@@H]2[C@]3(CC[C@@H]4[C@@]5(C)C(=O)C=C[C@H](O)[C@@]65O[C@@H]6C[C@H]4[C@@H]3CC2)C)C)C(C)=C(CO)C(=O)O1 DBRXOUCRJQVYJQ-CKNDUULBSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- SBZWTSHAFILOTE-SOUVJXGZSA-N (2R,3S,4S)-leucocyanidin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3[C@H](O)[C@@H]2O)=CC=C(O)C(O)=C1 SBZWTSHAFILOTE-SOUVJXGZSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
- KDMWWIREEDECOR-UHFFFAOYSA-N 1-amino-2-(hydroxymethyl)anthracene-9,10-dione Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC(CO)=C2N KDMWWIREEDECOR-UHFFFAOYSA-N 0.000 description 1
- XAWPKHNOFIWWNZ-UHFFFAOYSA-N 1h-indol-6-ol Chemical compound OC1=CC=C2C=CNC2=C1 XAWPKHNOFIWWNZ-UHFFFAOYSA-N 0.000 description 1
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
- LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 description 1
- AYPZAZPOYROADP-UHFFFAOYSA-N 2-(2-phenylethenyl)phenol Chemical class OC1=CC=CC=C1C=CC1=CC=CC=C1 AYPZAZPOYROADP-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- GYFFKZTYYAFCTR-JUHZACGLSA-N 4-O-trans-caffeoylquinic acid Chemical compound O[C@@H]1C[C@](O)(C(O)=O)C[C@@H](O)[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 GYFFKZTYYAFCTR-JUHZACGLSA-N 0.000 description 1
- PWWCDTYUYPOAIU-DHZHZOJOSA-N 4-hydroxychalcone Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=CC=C1 PWWCDTYUYPOAIU-DHZHZOJOSA-N 0.000 description 1
- GZSOSUNBTXMUFQ-NJGQXECBSA-N 5,7,3'-Trihydroxy-4'-methoxyflavone 7-O-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 GZSOSUNBTXMUFQ-NJGQXECBSA-N 0.000 description 1
- GYFFKZTYYAFCTR-UHFFFAOYSA-N 5-O-(6'-O-galloyl)-beta-D-glucopyranosylgentisic acid Natural products OC1CC(O)(C(O)=O)CC(O)C1OC(=O)C=CC1=CC=C(O)C(O)=C1 GYFFKZTYYAFCTR-UHFFFAOYSA-N 0.000 description 1
- NPUWPQJIMKMGDE-UHFFFAOYSA-N 5-[2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,3-diol Chemical compound OC1=CC(O)=CC(C=CC=2C=C(O)C=C(O)C=2)=C1 NPUWPQJIMKMGDE-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- NOEGNKMFWQHSLB-UHFFFAOYSA-N 5-hydroxymethylfurfural Chemical compound OCC1=CC=C(C=O)O1 NOEGNKMFWQHSLB-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 244000298697 Actinidia deliciosa Species 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 235000016413 Actinidia polygama Nutrition 0.000 description 1
- 240000006274 Actinidia polygama Species 0.000 description 1
- 241000222518 Agaricus Species 0.000 description 1
- 244000307697 Agrimonia eupatoria Species 0.000 description 1
- 235000007756 Akebia quinata Nutrition 0.000 description 1
- 240000008027 Akebia quinata Species 0.000 description 1
- 235000013668 Aloysia triphylla Nutrition 0.000 description 1
- 240000008554 Aloysia triphylla Species 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 241001444063 Aronia Species 0.000 description 1
- 235000008725 Artocarpus heterophyllus Nutrition 0.000 description 1
- 244000025352 Artocarpus heterophyllus Species 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 240000006914 Aspalathus linearis Species 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 102100028266 Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 2 Human genes 0.000 description 1
- 101710102057 Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 2 Proteins 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 241000269333 Caudata Species 0.000 description 1
- 235000005940 Centaurea cyanus Nutrition 0.000 description 1
- 240000004385 Centaurea cyanus Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 239000004155 Chlorine dioxide Substances 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241000132536 Cirsium Species 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000175448 Citrus madurensis Species 0.000 description 1
- 235000001759 Citrus maxima Nutrition 0.000 description 1
- 244000276331 Citrus maxima Species 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 240000004784 Cymbopogon citratus Species 0.000 description 1
- 235000017897 Cymbopogon citratus Nutrition 0.000 description 1
- 244000019459 Cynara cardunculus Species 0.000 description 1
- 235000019106 Cynara scolymus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- 235000007630 Elaeagnus umbellata var parvifolia Nutrition 0.000 description 1
- 244000138900 Elaeagnus umbellata var. parvifolia Species 0.000 description 1
- 235000015489 Emblica officinalis Nutrition 0.000 description 1
- 241001362421 Epimedium brevicornu Species 0.000 description 1
- 241000208688 Eucommia Species 0.000 description 1
- 235000012601 Euterpe oleracea Nutrition 0.000 description 1
- 244000207620 Euterpe oleracea Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000017317 Fortunella Nutrition 0.000 description 1
- 244000307700 Fragaria vesca Species 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- 240000008609 Gloriosa superba Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 240000007829 Haematoxylum campechianum Species 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000758791 Juglandaceae Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000013628 Lantana involucrata Nutrition 0.000 description 1
- 240000005183 Lantana involucrata Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 235000002156 Lilium lancifolium Nutrition 0.000 description 1
- 244000108452 Litchi chinensis Species 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 235000014837 Malpighia glabra Nutrition 0.000 description 1
- 240000003394 Malpighia glabra Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 240000006236 Martynia annua Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 235000016357 Mirtillo rosso Nutrition 0.000 description 1
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 235000015742 Nephelium litchi Nutrition 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- CKMNPXWFAZLBNK-QOFYEYOWSA-N OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O Chemical group OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O CKMNPXWFAZLBNK-QOFYEYOWSA-N 0.000 description 1
- PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 1
- 240000001439 Opuntia Species 0.000 description 1
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 description 1
- 241000179039 Paenibacillus Species 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 102100026367 Pancreatic alpha-amylase Human genes 0.000 description 1
- 235000006579 Pasania edulis Nutrition 0.000 description 1
- 244000185701 Pasania edulis Species 0.000 description 1
- 235000011925 Passiflora alata Nutrition 0.000 description 1
- 235000011922 Passiflora incarnata Nutrition 0.000 description 1
- 235000013750 Passiflora mixta Nutrition 0.000 description 1
- 235000013731 Passiflora van volxemii Nutrition 0.000 description 1
- 235000000556 Paullinia cupana Nutrition 0.000 description 1
- 240000003444 Paullinia cupana Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 description 1
- 240000009120 Phyllanthus emblica Species 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 235000008180 Piper betle Nutrition 0.000 description 1
- 240000008154 Piper betle Species 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 235000015926 Proboscidea louisianica ssp. fragrans Nutrition 0.000 description 1
- 235000015925 Proboscidea louisianica subsp. louisianica Nutrition 0.000 description 1
- 235000019096 Proboscidea parviflora Nutrition 0.000 description 1
- 235000011158 Prunus mume Nutrition 0.000 description 1
- 244000018795 Prunus mume Species 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 235000010580 Psophocarpus tetragonolobus Nutrition 0.000 description 1
- 244000046095 Psophocarpus tetragonolobus Species 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 241000208422 Rhododendron Species 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 241001312569 Ribes nigrum Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 241001635574 Sabatia angularis Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000218998 Salicaceae Species 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 244000151637 Sambucus canadensis Species 0.000 description 1
- 235000018735 Sambucus canadensis Nutrition 0.000 description 1
- 241000269851 Sarda sarda Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 241000220286 Sedum Species 0.000 description 1
- 240000003705 Senecio vulgaris Species 0.000 description 1
- 241000533293 Sesbania emerus Species 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000014570 Stauntonia hexaphylla Nutrition 0.000 description 1
- 240000001490 Stauntonia hexaphylla Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 244000125380 Terminalia tomentosa Species 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 241000186339 Thermoanaerobacter Species 0.000 description 1
- 241000205188 Thermococcus Species 0.000 description 1
- 235000017715 Thymus pulegioides Nutrition 0.000 description 1
- 240000006001 Thymus serpyllum Species 0.000 description 1
- 235000004054 Thymus serpyllum Nutrition 0.000 description 1
- 240000007313 Tilia cordata Species 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- LUEWUZLMQUOBSB-UHFFFAOYSA-N UNPD55895 Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(OC3C(OC(O)C(O)C3O)CO)C(O)C2O)CO)C(O)C1O LUEWUZLMQUOBSB-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 235000003650 acai Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 description 1
- 125000003691 alpha-D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium peroxydisulfate Substances [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 1
- VAZSKTXWXKYQJF-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)OOS([O-])=O VAZSKTXWXKYQJF-UHFFFAOYSA-N 0.000 description 1
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- LSOTZYUVGZKSHR-UHFFFAOYSA-N anthracene-1,4-dione Chemical compound C1=CC=C2C=C3C(=O)C=CC(=O)C3=CC2=C1 LSOTZYUVGZKSHR-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000016520 artichoke thistle Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 235000007123 blue elder Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- XQKKWWCELHKGKB-UHFFFAOYSA-L calcium acetate monohydrate Chemical compound O.[Ca+2].CC([O-])=O.CC([O-])=O XQKKWWCELHKGKB-UHFFFAOYSA-L 0.000 description 1
- 229940067460 calcium acetate monohydrate Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- GBAOBIBJACZTNA-UHFFFAOYSA-L calcium sulfite Chemical compound [Ca+2].[O-]S([O-])=O GBAOBIBJACZTNA-UHFFFAOYSA-L 0.000 description 1
- 235000010261 calcium sulphite Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 235000019398 chlorine dioxide Nutrition 0.000 description 1
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical class OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000000125 common agrimony Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 235000020237 cranberry extract Nutrition 0.000 description 1
- GYFFKZTYYAFCTR-LMRQPLJMSA-N cryptochlorogenic acid Natural products O[C@H]1C[C@@](O)(C[C@H](O)[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O GYFFKZTYYAFCTR-LMRQPLJMSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- PGZIKUPSQINGKT-UHFFFAOYSA-N dialuminum;dioxido(oxo)silane Chemical compound [Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O PGZIKUPSQINGKT-UHFFFAOYSA-N 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- IGBKNLGEMMEWKD-UHFFFAOYSA-N diosmin Natural products COc1ccc(cc1)C2=C(O)C(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 IGBKNLGEMMEWKD-UHFFFAOYSA-N 0.000 description 1
- FGRVOLIFQGXPCT-UHFFFAOYSA-L dipotassium;dioxido-oxo-sulfanylidene-$l^{6}-sulfane Chemical compound [K+].[K+].[O-]S([O-])(=O)=S FGRVOLIFQGXPCT-UHFFFAOYSA-L 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 235000007124 elderberry Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000004993 emission spectroscopy Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940093497 ergothioneine Drugs 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 229940080322 erythrosine sodium Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LRMHFDNWKCSEQU-UHFFFAOYSA-N ethoxyethane;phenol Chemical compound CCOCC.OC1=CC=CC=C1 LRMHFDNWKCSEQU-UHFFFAOYSA-N 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- FNAZRRHPUDJQCJ-UHFFFAOYSA-N henicosane Chemical compound CCCCCCCCCCCCCCCCCCCCC FNAZRRHPUDJQCJ-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000002483 hydrogen compounds Chemical class 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 229920001461 hydrolysable tannin Polymers 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- OGMGXKJQIOUTTB-RGMNGODLSA-N hydron;(1s)-1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol;bromide Chemical compound Br.OC1=C(O)C=C2[C@H](C)NCCC2=C1 OGMGXKJQIOUTTB-RGMNGODLSA-N 0.000 description 1
- XLSMFKSTNGKWQX-UHFFFAOYSA-N hydroxyacetone Chemical compound CC(=O)CO XLSMFKSTNGKWQX-UHFFFAOYSA-N 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- RJGBSYZFOCAGQY-UHFFFAOYSA-N hydroxymethylfurfural Natural products COC1=CC=C(C=O)O1 RJGBSYZFOCAGQY-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- OVGXLJDWSLQDRT-CEOVSRFSSA-L magnesium;(2s)-2-hydroxypropanoate Chemical compound [Mg+2].C[C@H](O)C([O-])=O.C[C@H](O)C([O-])=O OVGXLJDWSLQDRT-CEOVSRFSSA-L 0.000 description 1
- UYQJCPNSAVWAFU-UHFFFAOYSA-N malto-tetraose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)O1 UYQJCPNSAVWAFU-UHFFFAOYSA-N 0.000 description 1
- LUEWUZLMQUOBSB-OUBHKODOSA-N maltotetraose Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O[C@@H]3[C@@H](O[C@@H](O)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-OUBHKODOSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- DJEHXEMURTVAOE-UHFFFAOYSA-M potassium bisulfite Chemical compound [K+].OS([O-])=O DJEHXEMURTVAOE-UHFFFAOYSA-M 0.000 description 1
- 229940099427 potassium bisulfite Drugs 0.000 description 1
- 235000010259 potassium hydrogen sulphite Nutrition 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 1
- 235000019252 potassium sulphite Nutrition 0.000 description 1
- GWTUHAXUUFROTF-UHFFFAOYSA-N pseudochlorogenic acid Natural products C1C(O)C(O)C(O)CC1(C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 GWTUHAXUUFROTF-UHFFFAOYSA-N 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 125000000953 rutinose group Chemical group 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- IBRKLUSXDYATLG-UHFFFAOYSA-N salsolinol hydrobromide Natural products OC1=C(O)C=C2C(C)NCCC2=C1 IBRKLUSXDYATLG-UHFFFAOYSA-N 0.000 description 1
- 238000002098 selective ion monitoring Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020083 shōchū Nutrition 0.000 description 1
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 1
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000000551 statistical hypothesis test Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- RLNWRDKVJSXXPP-UHFFFAOYSA-N tert-butyl 2-[(2-bromoanilino)methyl]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1CNC1=CC=CC=C1Br RLNWRDKVJSXXPP-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 108010021724 tonin Proteins 0.000 description 1
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Definitions
- the present invention relates to an oral beauty agent, and more particularly, to an oral beauty agent for improving yellowing, texture, and skin quality of skin.
- beauty foods are similar to ordinary foods and beverages in that they are taken orally, they are usually common in that specific nutrients and functional ingredients are enhanced to achieve the desired purpose. It is different from food and drink. In addition, beauty foods are not intended to have immediate effects like drugs or to treat specific diseases, and it is difficult to ingest sufficient amounts of ordinary foods and beverages. It differs from pharmaceuticals in that it is intended to supplement specific nutrients and functional ingredients that are useful for beauty. Examples of beauty foods include oral compositions containing nutrients and functional ingredients useful for beauty such as chondroitin sulfate, coenzyme Q10, hyaluronic acid, and glucosamine, as described in Patent Documents 1 and 2. .
- Patent Document 3 discloses a melanin-lowering agent and a skin lightness-lowering inhibitor containing ⁇ -glycosyl hesperidin, which are used as foods and drinks or oral preparations, but they reduce the amount of melanin in the skin.
- the skin yellowness is an index completely different from the skin lightness (for example, Non-Patent Document 1). 2), texture, and means for improving skin quality and means for improving inconvenience when orally ingesting ⁇ -glycosyl hesperidin are not disclosed.
- Patent Document 4 discloses means for improving skin color using ⁇ -glycosyl hesperidin, which is based on an external preparation for skin containing ⁇ -glycosyl hesperidin. External preparations are clearly different from cosmetic foods that are orally ingested in the form of administration or usage.
- Non-Patent Document 1 Yoko Yashiki, “Fragrance JOURNAL”, Vol. 40, No. 4, pp. 80-82, 2012
- Non-Patent Document 2 Yuji Kajita, “Color Material”, Vol. 76, No. 2, pp. 78-83, 2003
- an object of the present invention is to provide an oral beauty agent that can effectively improve the yellowish dullness, texture, and skin quality of the skin.
- the oral beauty agent according to the present invention is not only a beauty food to be taken orally, but also in the form of a health food, nutritional functional food, health functional food, food for specified health, etc. for the purpose of improving beauty. Is included.
- the present inventors have made extensive research efforts, and as a result, when a human being continuously orally ingests glycosyl hesperetin on a daily basis, the skin yellowing, texture, and skin quality are effective.
- the present invention was completed by newly finding that it can be improved and establishing its application.
- the present invention solves the above-mentioned problems by providing an oral cosmetic agent for improving yellowness, texture, and skin quality containing glycosyl hesperetin as an active ingredient.
- glycosyl hesperetin as used in the present specification means all compounds in which saccharides are bound to hesperetin, that is, all compounds having a hesperetin skeleton, and specific examples thereof include hesperidin and the rhamnose group constituting hesperidin's rutinose. 7-O- ⁇ -glucosyl hesperetin having a structure, and ⁇ -glycosyl hesperidin in which a saccharide (eg, a saccharide such as D-glucose, D-fructose, or D-galactose) is ⁇ -linked in an equimolar amount or more to hesperidin It is done.
- a saccharide eg, a saccharide such as D-glucose, D-fructose, or D-galactose
- hesperidin also called vitamin P
- vitamin P has a structure in which rutinose composed of rhamnose and glucose is bound to hesperetin.
- the compound is represented by the structural formula shown in the following chemical formula 1 and is often contained in citrus peels and the like. It is a component.
- 7-O- ⁇ -glucosyl hesperetin is a compound represented by the structural formula shown in the following chemical formula 2, and has a feature of being highly water-soluble compared to hesperidin.
- 7-O- ⁇ -glucosyl hesperetin is produced by, for example, causing ⁇ -L-rhamnosidase (EC 3.2.1.40) to act on a solution containing ⁇ -glucosyl hesperidin and hesperidin as disclosed in Patent Document 1. Can be manufactured.
- ⁇ -glycosyl hesperidin is a compound in which saccharide (eg, saccharides such as D-glucose, D-fructose, or D-galactose) is ⁇ -linked to hesperidin in an equimolar amount or more.
- saccharide eg, saccharides such as D-glucose, D-fructose, or D-galactose
- a typical example of ⁇ -glycosyl hesperidin is ⁇ -glucosyl hesperidin represented by the structural formula shown in the following chemical formula 3 in which one glucose ⁇ -links to glucose in the rutinose structure of hesperidin (also known as enzyme-treated hesperidin, glycosylated hesperidin). , Water-soluble hesperidin, or sugar transfer vitamin P).
- the trade name “Hayashibara Hesperidin (registered trademark) S” is commercially available.
- glycosyl hesperetin itself is a safe and highly versatile compound that has been widely used as a material for various foods, cosmetics, pharmaceuticals, quasi drugs, and the like.
- ⁇ -glycosyl hesperidin is more water-soluble than hesperidin and 7-O- ⁇ -glucosyl hesperetin, and is easy to handle. In vivo, it is the same as hesperidin and 7-O- ⁇ -glucosyl hesperetin. It is hydrolyzed to hesperetin under the action of in vivo enzymes, and exhibits the physiological activity inherent in hesperetin.
- the oral cosmetic preparation of the present invention is an oral cosmetic preparation containing glycosyl hesperetin as an active ingredient, and can be ingested safely and easily by humans on a daily basis, and can be taken orally without discomfort, and is industrially inexpensive. Can be provided. According to such an oral beauty agent of the present invention, yellowish dullness, texture, and skin quality can be effectively improved.
- the oral beauty agent of the present invention is a so-called working woman who applies to women in their 40s and older who are concerned about yellowing of skin, roughness of skin, and deterioration of skin quality. When it does, it has the outstanding characteristic that a desired effect is exhibited more notably than other subjects.
- glycosyl hesperetin contained in the oral cosmetic agent of the present invention as an active ingredient means that human beings can be taken orally on a daily basis safely and easily without discomfort, and can be provided industrially at low cost. As long as the intended effects of the present invention can be achieved, the origin, production method, purity and the like can be used without particular limitation.
- glycosyl hesperetin referred to in the present specification means a general compound in which a saccharide is bound to hesperetin, as described above, and more specifically, hesperidin that generates hesperetin by the action of an in vivo enzyme. , 7-O- ⁇ -glucosyl hesperetin, and ⁇ -glycosyl hesperidin.
- glycosyl hesperetins if humans can safely and easily, and miscellaneous taste, coloring, odor and the like are significantly or significantly reduced, can be taken orally without discomfort, and can be provided industrially at low cost, Whether it is a commercially available product or a conventionally known production method, it can be used more suitably in the present invention. Since the present invention is not an invention relating to a method for producing glycosyl hesperetin itself, the details of the production method are omitted in the present specification, but the outline thereof is as follows.
- glycosyl hesperetins used in the present invention hesperidin is industrially extracted from citrus fruits, pericarp, seeds, immature fruits, etc., which are hesperidin-containing plants, and appropriately extracted with a solvent such as water or alcohol. The desired amount can be produced.
- ⁇ -glycosyl hesperidin is a glycosyltransferase in a solution containing hesperidin and an ⁇ -glucosyl sugar compound as disclosed in, for example, JP-A No. 11-346792.
- ⁇ -glycosyl hesperidin which is collected, and the desired amount can be industrially produced at low cost.
- 7-O- ⁇ -glucosyl hesperetin is obtained by combining ⁇ -glycosyl hesperidin and hesperidin obtained by the action of glycosyltransferase.
- ⁇ -L-rhamnosidase act on the contained enzyme reaction solution to produce 7-O- ⁇ -glucosyl hesperetin and collecting this, the desired amount can be industrially produced at low cost.
- glycosyl hesperetin used in the present invention among the commercially available products and glycosyl hesperetins obtained by a conventionally known production method, a high-purity product with less impurities is preferably used.
- glycosyl hesperetin-containing composition which contains a physiologically acceptable ionic compound, which is produced in a secondary manner in the form of a so-called so-called glycosyl hesperetin.
- glycosyl hesperetin is mainly used as a contaminant, an unreacted raw material derived from the manufacturing raw material, or a physiologically produced physiologically secondary product in the manufacturing process.
- a glycosyl hesperetin-containing composition comprising an acceptable ionic compound is simply referred to as glycosyl hesperetin.
- the glycosyl hesperetin used in the present invention includes high-purity glycosyl hesperetin obtained through a crystallization step.
- the present inventors have proposed a conventional method for reducing the content of concomitant substances contained in conventional glycosyl hesperidin for the purpose of eliminating miscellaneous taste, coloring, etc., which were disadvantages of the conventionally known glycosyl hesperetin.
- Glycosyl hesperetin with reduced odor hereinafter referred to as “miscellaneous taste, etc.” in some cases
- miscellaneous taste and coloration by improving a part thereof
- the manufacturing method was established and disclosed in Japanese Patent Application No. 2014-41066 and International Patent Application No. PCT / JP2015 / 056230 pamphlet. Glycosyl hesperetin with reduced miscellaneous taste, etc.
- glycosyl hesperetin with reduced miscellaneous taste and the like can be advantageously used as the most suitable glycosyl hesperetin for carrying out the present invention.
- glycosyl hesperetin with reduced miscellaneous taste and its physical properties
- Glycosyl hesperetin with reduced miscellaneous tastes is obtained by (a) preparing an aqueous solution containing hesperidin and a partial degradation product of starch, and (b) glycosyl containing ⁇ -glucosyl hesperidin by allowing a glycosyltransferase to act on the obtained aqueous solution.
- a production method comprising a step of producing a hesperetin-containing composition and (c) a step of collecting the produced glycosyl hesperetin-containing composition, wherein one or two or more of the steps (a) to (c) above are performed as a reducing agent.
- glycosyl hesperetin prepared through the reducing agent treatment step may be referred to as “reducing agent-treated product”), enzyme reaction ( (Transglycosylation reaction, etc.), reducing agent treatment, and purification method will be sequentially described.
- hesperidin which is a raw material for producing a reducing agent-treated product
- any of the conventional hesperidins used in the production of glycosyl hesperetin can be used.
- Squeezed liquid, or a partially purified product thereof may be used in appropriate combination of one or more.
- hesperidin-containing plant examples include citrus fruits belonging to the genus Citrus mandarin, such as mandarin oranges, oranges, perfumed citrus fruits, miscellaneous citrus fruits, tangoles, tanzeros, buntans, and kumquats.
- Citrus mandarin such as mandarin oranges, oranges, perfumed citrus fruits, miscellaneous citrus fruits, tangoles, tanzeros, buntans, and kumquats.
- hesperidin-containing site examples include citrus fruits, pericarps, seeds, and immature fruits.
- any glycosyltransferase can be used as long as it can transfer to hesperidin to produce ⁇ -glycosyl hesperidin as glycosyl hesperetin when a glycosyltransferase described below is allowed to act.
- Dextrin, cyclodextrin, malto-oligosaccharide and other starch partial decomposition products, and one or more starch partial decomposition products selected from liquefied starch, gelatinized starch and the like are appropriately selected.
- the amount of the partially decomposed starch used in the enzyme reaction described later is usually about 0.1 to about 150 times, preferably about 1 to about 100 times, more preferably, relative to the mass of the raw material hesperidin. Is used in an amount selected from the range of about 2 to about 50 times.
- the sugar derived from the partial starch degradation product is transferred to hesperidin, and ⁇ -glycosyl hesperidin is efficiently produced.
- excess unreacted hesperidin remains in the enzymatic reaction system as much as possible. It is desirable to use an amount of starch partial degradation product.
- the reason for this is that, in the purification step described later, the partially decomposed starch and saccharides derived therefrom can be separated from ⁇ -glycosyl hesperidin relatively easily, whereas hesperidin behaves together with ⁇ -glycosyl hesperidin, This is because it is difficult to separate from ⁇ -glycosyl hesperidin, so that if the remaining amount of unreacted hesperidin is extremely low, the resulting glycosyl hesperetin has a disadvantage that the water solubility of the resulting glycosyl hesperetin is low.
- the enzyme reaction referred to in the present specification means an enzyme reaction in which ⁇ -glycosyl hesperidin is produced by allowing glycosyltransferase to act on hesperidin as a raw material for production and a partially degraded starch.
- glycosyltransferase used in the enzyme reaction, ⁇ -glucosidase (EC 3.2.1.20), cyclomaltodextrin glucanotransferase (EC 2.4.1.19, hereinafter referred to as “CGTase”). ), ⁇ -amylase (EC 3.2.1.1) and the like.
- Examples of the ⁇ -glucosidase include enzymes derived from animal and plant tissues such as pig liver and buckwheat seeds, or Aspergillus genus such as Mucor, Penicillium, and Aspergillus niger.
- CGTase examples include those derived from mold cultures belonging to the above, or those obtained by culturing microorganisms such as yeast belonging to the genus Saccharomyces in a nutrient medium, such as Bacillus genus. , Geobacillus genus, Klebsiella genus, Paenibacillus genus, Thermococcus genus, Sir Ana erotic Citrobacter (Thermoanaerobacter) genus Brevibacterium (Brevibacterium) genus Pyrococcus (Pyrococcus) genus Brevibacillus (Brevibacillus) genus, and it can be exemplified those Saccharomyces (Saccharomyces) genus from.
- microorganisms such as yeast belonging to the genus Saccharomyces in a nutrient medium, such as Bacillus genus. , Geobacillus genus, Klebsiella genus
- ⁇ -amylase one or two or more kinds derived from bacteria belonging to the genus Aspergillus such as bacteria belonging to the genus Geobacillus or Aspergillus niger are appropriately combined. Can be used.
- These glycosyltransferases can be either natural or genetically modified as long as the object of the present invention can be achieved, and if there are commercially available products, they can also be used as appropriate. Moreover, it is not always necessary to purify and use any of the above-mentioned glycosyltransferases. Usually, even a crude enzyme can be used as long as the object of the present invention can be achieved.
- the production rate of ⁇ -glycosyl hesperidin can be increased by adopting a partially degraded starch suitable for the glycosyltransferase.
- malto-oligosaccharides such as maltose, maltotriose, maltotetraose, or dextrose equivalent (DE) from about 10 to about 70 starch partial degradation products, when CGTase is used, From ⁇ -, ⁇ -, or ⁇ -cyclodextrin or starch paste of DE1 or less to a starch partial degradation product of DE about 60, and further, when ⁇ -amylase is used, from starch paste of DE1 or less to DE A partially decomposed starch such as 30 dextrins is preferably used.
- DE dextrose equivalent
- a solution containing hesperidin as high as possible is desirable, for example, a suspension containing hesperidin in a suspended state, dissolved in a solvent such as water at a high temperature of room temperature or higher, or A solution containing a high concentration of hesperidin dissolved in an alkali side pH exceeding 7.0 with an alkali agent is preferably used.
- alkaline agent examples include one or two or more strong alkaline aqueous solutions of about 0.1 to about 1.0 N sodium hydroxide aqueous solution, potassium hydroxide aqueous solution, sodium carbonate aqueous solution, calcium hydroxide aqueous solution, aqueous ammonia and the like. Can be used as appropriate.
- the concentration of hesperidin when hesperidin is used in the form of a solution using an alkaline agent is usually about 0.005 w / v% or more, preferably about 0.05 to about 10 w / v%, more preferably about 0.5. To about 10 w / v%, more preferably about 1 to about 10 w / v%.
- hesperidin when hesperidin is used in a suspended form without using an alkaline agent, hesperidin is suspended in a solvent such as water to form a suspended hesperidin, and the concentration of hesperidin is usually about 0.1 to about 2 w / v%, more preferably about 0.2 to about 2 w / v%, more preferably about 0.3 to about 2 w / v%.
- the temperature and time when glycosyltransferase is allowed to act on hesperidin and starch partial degradation products are the concentrations of hesperidin and starch partial degradation products used in the enzymatic reaction, the type of glycosyltransferase, the optimum temperature, the optimum pH, or the action.
- about 50 to about 100.degree. C. preferably about 60 to about 90.degree. C., more preferably about 70 to about 90.degree. C., and about 5 to about 100 hours.
- it is in the range of about 10 to about 80 hours, more preferably about 20 to about 70 hours.
- the pH and temperature when glycosyltransferase is allowed to act on an alkaline solution containing a high concentration of hesperidin depends on the type of glycosyltransferase, the optimum pH, the optimum temperature, the amount of action, and the concentration of hesperidin. As high as possible at which the glycosyltransferase can act, as high as possible, specifically about pH 7.5 to about 10, preferably about pH 8 to about 10, and about 40 to about 80 ° C. More preferably, the temperature is in the range of about 50 to about 80 ° C. Since hesperidin in the alkaline solution is liable to decompose, it is desirable to keep hesperidin as light-shielded and anaerobic as possible in order to prevent this.
- the pH at which glycosyltransferase acts on suspended hesperidin varies depending on the type of glycosyltransferase, the optimum temperature, the optimum pH, or the amount of action, and the concentration of suspended hesperidin.
- the pH is in the range of about 4 to about 7, preferably about 4.5 to about 6.5.
- hesperidin-rich solution in order to increase the solubility of hesperidin before the enzyme reaction and facilitate the transglycosylation reaction to hesperidin, it is highly compatible with water in a hesperidin-rich solution, particularly in a hesperidin-rich aqueous solution.
- An appropriate amount of an organic solvent such as methanol, ethanol, n-propanol, iso-propanol, n-butanol, acetol, acetone, and other lower alcohols, lower ketones, and the like may be optionally present together.
- the amount of enzyme and reaction time are closely related, and usually from an economic viewpoint, about 5 to about 150 hours, preferably about 10 to about 100 hours, more preferably about 20 to about 80 hours.
- the amount of the enzyme that completes the enzymatic reaction may be appropriately set according to the type of glycosyltransferase used. In addition, it is optional to repeat the reaction in batch mode using the immobilized glycosyltransferase or to perform the reaction in a continuous mode.
- the enzyme reaction solution containing ⁇ -glycosyl hesperidin and hesperidin obtained after the glycosyltransferase reaction is used as it is or after purification with a porous synthetic adsorption resin, if necessary, and then glucoamylase (EC 3.2.1). .3), or by partial hydrolysis with an amylase such as ⁇ -amylase (EC 3.2.1.2) to reduce the number of ⁇ -D-glucosyl groups of ⁇ -glycosyl hesperidin.
- glucoamylase is allowed to act, a polymer higher than ⁇ -maltosyl hesperidin can be hydrolyzed to produce glucose and to produce and accumulate ⁇ -glucosyl hesperidin.
- ⁇ -amylase when allowed to act, a polymer higher than ⁇ -maltotriosyl hesperidin is hydrolyzed to generate maltose, and a mixture containing ⁇ -glucosyl hesperidin and ⁇ -maltosyl hesperidin is generated. Can be accumulated.
- glucoamylase and ⁇ -L-rhamnosidase have a close relationship between the amount of the enzyme and the enzyme reaction time.
- about 5 to about 150 hours preferably The amount of the enzyme that completes the enzyme reaction in about 10 to about 100 hours, more preferably in about 20 to about 80 hours, may be appropriately set according to the type of enzyme. It is also possible to carry out the reaction repeatedly in batch mode using immobilized ⁇ -L-rhamnosidase, or to perform reaction in a continuous mode without interruption.
- the reducing agent treatment referred to in the specification of the present application means that a specific reducing agent is used, and the miscellaneous taste and coloring of glycosyl hesperetin (hereinafter sometimes abbreviated as “miscellaneous taste / coloring”), and further the odor is significant or It means a treatment for remarkably reducing, and (a) a step of preparing an aqueous solution containing hesperidin and a partial degradation product of starch, and (a) a glycosyltransferase acting on the resulting aqueous solution -Used in one or more of the steps of producing a glycosyl hesperetin-containing composition containing glucosyl hesperidin and (c) collecting the produced glycosyl hesperetin-containing composition, or (a) to (c) It means that the predetermined amount is added to the starting material before one or more steps and / or the resulting product after the steps.
- the reducing agent used in the method for producing glycosyl hesperetin with reduced miscellaneous taste is not particularly limited as long as the intended purpose of the present invention can be achieved, and general-purpose inorganic and organic reducing agents in the field. Any of the agents can be used. However, since the glycosyl hesperetin or high-purity glycosyl hesperetin used in the present invention including the reducing agent-treated product is mainly assumed to be applied to humans, it is highly safe, stable and easy to handle. It is desirable to use an excellent reducing agent.
- the former reducing agent can significantly reduce the miscellaneous taste of glycosyl hesperetin prepared without the treatment of the reducing agent, and the coloring and off-flavor can be further reduced. Since a significantly reduced high-quality glycosyl hesperetin can be provided, it can be more suitably used in the present invention. Although the reason is not clear, it is presumed as follows.
- the organic reducing agent when used for the purpose of the present invention, has a lower effect of reducing the taste / coloration compared to the inorganic reducing agent, or the organic reducing agent is an organic substance, so If the degradation product or modification product of the organic reducing agent remains without being completely removed in the purification process of the reducing agent-treated product, they may remain in the final product glycosyl hesperetin. This may be due to the negative impact on quality.
- sulfites (Also referred to as sulfites) is a reducing agent that can be more suitably used in the present invention because it is excellent in terms of safety, stability, and handleability.
- inorganic reducing agents such as sodium sulfite, potassium sulfite, sodium hydrogen sulfite, sodium hyposulfite, potassium hyposulfite, sodium pyrosulfite, potassium pyrosulfite, sodium metasulfite, potassium metasulfite, sodium metabisulfite, and meta Sulphites such as potassium bisulfite can be most suitably used in the present invention.
- the reducing agent is applied to one step in the production process of glycosyl hesperetin with reduced miscellaneous taste or the like, or the starting material before and / or the resultant product after that step.
- the appropriate amount is appropriately subdivided into the starting material before and / or the resulting material before the process, the intended object of the present invention can be efficiently achieved with a smaller amount of reducing agent. Can do.
- the total amount of the reducing agent added in each of the steps (a) to (c), after the (a) enzyme reaction (when other enzymes other than glycosyltransferase are used, all of them are used). Is usually 0.001% or more, preferably 0.01 to 3%, more preferably 0.01 to 1%, based on the mass of the enzyme reaction solution obtained after More preferably, an amount selected from a range corresponding to 0.01 to 0.5% is used.
- the reducing agent is added before the step (c)
- usually the remaining reducing agent is substantially removed in the purification step, thereby reducing the miscellaneous taste obtained as the final product. Is not substantially detected in the treated glycosylhesperetin.
- the amount of the reducing agent added in all the steps is generally 0.001% or more, preferably 0.01% or more, more preferably, in total, with respect to the mass of the enzyme reaction solution obtained after the enzyme reaction. Is added once or multiple times so as to be in the range of 0.01 to 1%.
- the temperature at the time of addition is usually the temperature employed in the steps (a) to (c), but it can also be set to a temperature higher than that temperature. Specifically, a temperature of room temperature or higher, preferably 50 ° C. or higher, more preferably 70 ° C. or higher, more preferably 80 ° C. or higher, and more preferably 90 to 120 ° C. can be exemplified.
- the enzyme reaction solution thus obtained can be directly used as glycosyl hesperetin with reduced miscellaneous taste and the like suitably used in the present invention.
- the enzyme reaction solution is appropriately combined with one or more means such as a separation method, a filtration method, a purification method using a porous synthetic resin, a concentration method, a spraying method, a drying method and the like known in the art.
- the product is treated with a reducing agent such as liquid, solid or powder.
- the porous synthetic resin means a synthetic resin such as a porous, wide adsorption surface area and nonionic styrene-divinylbenzene polymer, phenol-formalin resin, acrylate resin, methacrylate resin, for example.
- Amberlite XAD-1 Amberlite XAD-2, Amberlite XAD-4, Amberlite XAD-7, Amberlite XAD-8, Amberlite XAD-11, And resins such as Amberlite XAD-12; trade names manufactured by Mitsubishi Chemical Corporation: Diaion HP-10, Diaion HP-20, Diaion HP-30, Diaion HP-40, Diaion HP-50, Diamond Ion HP-2MG, Sepa beads SP70, Sepa beads SP 07, Sepabeads SP700, resins such as Sepabeads SP800; and IMACTI Ltd. trade name: Imakuti Syn-42, can be exemplified resins such Imakuti Syn-44, and Imakuti Syn-46.
- glycosyl hesperetin is adsorbed on the porous synthetic adsorbent, while remaining starch partially decomposes. Substances and water-soluble saccharides flow out of the column without being adsorbed.
- the glycosyl hesperetins hesperidin, 7-O- ⁇ -glucosyl hesperetin, and ⁇ -glycosyl hesperidin usually behave together and cannot be separated individually by the porous synthetic adsorbent.
- glycosyl hesperetin-containing eluate thus obtained is subjected to a distillation treatment to distill off the organic solvent, and then concentrated to a desired concentration to obtain a glycosyl hesperetin with reduced hesperidin content and reduced miscellaneous taste. can get.
- the elution operation of glycosyl hesperetin with the organic solvent also serves as a regeneration operation of the porous synthetic adsorbent, which has the advantage of enabling the porous synthetic adsorbent to be used repeatedly.
- glycosyl hesperetin with reduced liquid miscellaneous taste and the like is optionally dried and powdered by a known drying method to obtain a powdery glycosyl hesperetin that is preferably used in the present invention.
- the characteristic miscellaneous taste that was a disadvantage of glycosyl hesperetin prepared without the reducing agent treatment step (hereinafter sometimes referred to as “reducing agent non-treated product”) is significantly reduced,
- a reducing agent-treated product in which coloring and odor are effectively reduced can be produced.
- the taste / coloring or odor peculiar to the non-reducing agent-treated product does not substantially change only by applying the purification method. That is, for example, the purification method using the porous synthetic adsorbent, which is widely used in the manufacturing process of non-reducing agent treated products, is not only a partially decomposed product of starch and water-soluble saccharides but also impurities such as water-soluble salts.
- glycosyl hesperetin preferably used in the present invention in particular, a reducing agent-treated product has a significantly reduced miscellaneous taste, low electrical conductivity, and a reduced content of ionic compounds involved in electrical conductivity.
- the ionic compound include nariltin, diosmine, neoponcillin, which is originally contained in hesperidin as a raw material, or a compound such as glucosylnariltin and glucosylneoponcillin, which are enzyme reaction products, and their degradation.
- a compound closely related to the degradation product thereof, or a furfural as an index in the present invention which is considered to be derived from a raw material for producing glycosyl hesperetin or produced as a secondary product in the production process.
- compounds that liberate metal cations such as calcium, potassium, magnesium, and sodium in a solution state.
- the components such as nariltin, diosmin, neoponcillin, glucosylnariltin, glucosylneoponcillin are usually contained in a small amount in the reducing agent-treated product suitably used in the present invention.
- the mechanism by which reducing taste is used to obtain miscellaneous taste and coloration, especially glycosyl hesperetin with significantly reduced miscellaneous taste is not clear, but if estimated, It is as follows.
- the causative agent of the taste shown in the above (1) and (2) is modified by a reducing agent, and is easily separated from glycosyl hesperetin in a purification step using a porous synthetic adsorbent and the like. A significantly reduced reducing agent-treated product is obtained.
- examples of the glycosyl hesperetin preferably used in the present invention include those in which the glycosyl hesperetin-containing product and a reducing agent are contacted to significantly reduce the miscellaneous taste of the glycosyl hesperetin-containing product.
- Such a glycosyl hesperetin-containing product is also included in the reducing agent-treated product referred to in the present specification.
- the miscellaneous taste of the glycosyl hesperetin-containing product can be significantly reduced, and coloring and odor can be effectively reduced significantly.
- the contact between the glycosyl hesperetin-containing product and the reducing agent is preferably carried out in a solution state or a suspended state using an appropriate solvent such as water, rather than in a solid state.
- an appropriate solvent such as water
- examples of the glycosyl hesperetin-containing product with which the reducing agent is contacted include glycosyl hesperetin containing one or more selected from hesperidin, ⁇ -glycosyl hesperidin, and 7-O- ⁇ -glucosyl hesperetin.
- the glycosyl hesperetin-containing material is usually 70% by mass or more and less than 100% by mass (hereinafter, unless otherwise specified, “% by mass” is abbreviated as “%”) per dry solid. More preferable examples include glycosyl hesperetin containing 80% or more and less than 100%, and more preferably 90% or more and less than 100%.
- the reducing agent to be used can be the same as that used for producing a reducing agent-treated product.
- the amount of the reducing agent used is usually 0.00001% or more, preferably 0.0001 to 0.5%, more preferably 0.001 to 0.4 per dry solid of glycosyl hesperetin. %, More preferably in the range of 0.001 to 0.3%, mixing them uniformly and bringing the glycosyl hesperetin and the reducing agent into contact with each other to prepare without the above reducing agent treatment Even if it is a non-reducing agent treated product, the peculiar taste and the like can be significantly or remarkably reduced.
- liquid reducing agent-treated product is concentrated by a known concentration method to obtain a syrup-like or paste-like reducing agent-treated product, which is further dried by a known drying method to form a solid, granular, or powder. It is also optional to use a reducing agent-treated product.
- the reducing agent-treated product in which the peculiar taste and the like, which was a drawback of the non-reducing agent-treated product is significantly or significantly reduced. Can be obtained.
- the reducing agent-treated product obtained by the above production method is substantially free of furfural and is a kind of phenol ether, 4-vinylanisole (also called 4-methoxystyrene) (hereinafter referred to as “4-VA”). "Abbreviated as”.)
- 4-VA 4-methoxystyrene
- glycosyl hesperetins used in the present invention not only the miscellaneous taste is significantly reduced but also the coloring and odor are significantly reduced. In the present invention, it is most preferably used.
- the phrase “substantially free of furfural” refers to glycosyl hesperetin having a significantly lower level of furfural content than conventional products.
- GC / MS analysis method an analysis method using a gas chromatograph mass (GC / MS) analyzer shown in “(1) Furfural content” in Experiment 2 described later (hereinafter abbreviated as “GC / MS analysis method”).
- ppb gas chromatograph mass
- it means less than 20 ppb, more preferably less than 15 ppb, particularly preferably less than 10 ppb.
- glycosyl hesperetins of the present invention those in which the furfural content is reduced to below the detection limit of the GC / MS analysis method are significantly reduced in miscellaneous taste and markedly colored compared to the conventional product. It is a reduced, very high quality glycosyl hesperetin.
- the glycosyl hesperetin used in the present invention is blended in a composition for oral use by humans, it is not always necessary to have the highest purity. Therefore, the furfural content is below the detection limit. There is not necessarily a need to be reduced to a level, or a need to be free of furfural.
- the glycosyl hesperetin used in the present invention is not required to substantially contain furfural, and the amount of the glycosyl hesperetin is significantly smaller than the conventional product or less than the detection limit as long as the intended purpose of the present invention can be achieved.
- Furfural may be contained.
- the glycosyl hesperetin used in the present invention is more preferably one that does not substantially contain the above-mentioned furfural.
- the furfural content is less than about 320 ppb, preferably about Those having a molecular weight of less than 310 ppb can exhibit an action for improving or reducing yellowing of skin, so that these glycosyl hesperetins can also be used in the present invention.
- the 4-VA is a component presumed to be produced due to the production raw material of glycosyl hesperetin, and the content in the resulting glycosyl hesperetin is usually less than 30 ppb per dry solid, and 4-VA The content is usually in parallel with the furfural content when the furfural content is less than 200 ppb. It should be noted that “substantially free of 4-VA” means that the 4-VA content is significantly higher than that of other glycosyl hesperetin-containing compositions such as non-reducing agent treated products other than the reducing agent treated product, as in the case of furfural. Means being at a low level.
- the 4-VA content in the reducing agent-treated product was measured by an analytical method using a GC / MS analyzer shown in “(2) 4-VA content” in Experiment 2 described later.
- a GC / MS analyzer shown in “(2) 4-VA content” in Experiment 2 described later.
- less than 30 ppb preferably less than 15 ppb, more preferably less than 10 ppb, even more preferably less than 5 ppb, even more preferably less than 3 ppb, even more preferably less than 2 ppb per dry solid It is.
- the reducing agent-treated product has an excellent feature in which coloring (hereinafter, sometimes referred to as “coloring degree”) is significantly reduced as compared with the non-reducing agent-treated product.
- coloring degree of glycosyl hesperetin is measured by the method shown in “(3) Color tone and coloring degree” of Experiment 2 described later, and the outline thereof is as follows. That is, after an aqueous solution containing a predetermined concentration of glycosyl hesperetin is heat-treated in a sealed container, the color of the treatment liquid is visually observed, and the absorbance at a wavelength of 420 nm (OD 420 nm ) and the absorbance at a wavelength of 720 nm (OD) are measured by a spectrophotometer.
- the difference in absorbance at both wavelengths (OD 420 nm -OD 720 nm ) is determined, and the measured value is taken as the coloring degree.
- the difference in absorbance is less than 0.24, preferably 0.20 or less, more preferably 0.17 or less, still more preferably more than 0 and less than 0. What is 15 or less can be illustrated.
- heating the aqueous solution of glycosyl hesperetin is based on the fact that coloring due to heating of glycosyl hesperetin is due to the disadvantage that the degree of coloration of the non-reducing agent-treated product increases remarkably. It was set for the purpose of evaluation.
- the reducing agent-treated product is a glycosyl hesperetin-containing composition containing glycosyl hesperetin and a physiologically acceptable ionic compound, which is a 1 w / v% aqueous solution, heated at 100 ° C. for 30 minutes in a sealed container,
- the electrical conductivity at 20 ° C. is less than 10 ⁇ S / cm, preferably less than 8 ⁇ S / cm, more preferably less than 6 ⁇ S / cm, and even more preferably more than 0 ⁇ S / cm and more than 4.5 ⁇ S / cm.
- a glycosyl hesperetin-containing composition that is less than
- the physiologically acceptable ionic compound referred to in the present specification is essentially contained in a reducing agent-untreated product and a reducing agent-treated product, which is orally ingested by humans, apart from the amount of the physiologically acceptable ionic compound.
- a reducing agent-untreated product and a reducing agent-treated product, which is orally ingested by humans, apart from the amount of the physiologically acceptable ionic compound.
- safe physiologically acceptable ionic compounds that are either inherently contained in the raw material of manufacture or produced as a secondary product during the manufacturing process and are safe for ingestion by humans.
- Physiologically acceptable ionic compound are either inherently contained in the raw material of manufacture or produced as a secondary product during the manufacturing process and are safe for ingestion by humans.
- glycosyl hesperetin-containing composition for example, naryltin, diosmine, neoponcillin, or glucosylnariltin which is an enzyme reaction product, which is inherently included in the hesperidin raw material, It means a decomposition product such as glucosyl neoponcilin and a compound closely related to the decomposition product, and releases metal ions such as calcium, potassium, magnesium and sodium which are cationic metal elements in a solution state. Compound etc. are mentioned.
- the reducing agent-treated product obtained by the production method is a composition mainly composed of one or more glycosyl hesperetins selected from hesperidin, ⁇ -glycosyl hesperidin, and 7-O- ⁇ -glucosyl hesperetin.
- the total glycosyl hesperetin content per dry solid of the composition is usually 90% or more and less than 100%, preferably 93% or more and less than 100%, more preferably 95% or more. It is less than 100%, more preferably 97% or more and less than 100%, and still more preferably 98% or more and less than 100%.
- the ⁇ -glycosyl hesperidin content referred to in the present specification refers to a composition containing ⁇ -glycosyl hesperidin as a sample, which is diluted or dissolved to 0.1% (w / v) with purified water, and a 0.45 ⁇ m membrane.
- the sample was subjected to high performance liquid chromatography (HPLC) analysis under the following conditions, using the reagent hesperidin (sales by Wako Pure Chemical Industries, Ltd.) as a standard substance, and the peak area appearing in the chromatogram at UV 280 nm Calculated on the basis of the molecular weight of each component such as hesperidin, ⁇ -glycosyl hesperidin ( ⁇ -glucosyl hesperidin, etc.), and the content of each component in a composition converted to the amount of anhydrous substance.
- HPLC high performance liquid chromatography
- HPLC device “LC-20AD” (manufactured by Shimadzu Corporation)
- Degasser “DGU-20A3” (manufactured by Shimadzu Corporation)
- Sample injection amount 10 ⁇ 1
- Eluent water / acetonitrile / acetic acid (80/20 / 0.01 (volume ratio))
- Flow velocity 0.7 m1 / min
- Temperature 40 ° C
- Detection UV detector “SPD-20A” (manufactured by Shimadzu Corporation)
- Data processor “Chromatopack C-R7A” (manufactured by Shimadzu Corporation)
- Hesperidin content Analyzed by HPLC, and calculated based on the ratio of the peak area to the peak area of the reagent hesperidin (sold by Wako Pure Chemical Industries, Ltd.) as a standard substance with a predetermined concentration.
- ⁇ -glucosyl hesperidin content analyzed by HPLC, the ratio of the peak area to the peak area of the reagent hesperidin (sales of Wako Pure Chemical Industries, Ltd.) as a standard substance of a predetermined concentration, ⁇ -glycosyl hesperidin and Calculated based on the molecular weight ratio of hesperidin.
- glycosyl hesperetin content Analyzed by HPLC, the ratio of the peak area to the peak area of the reagent hesperidin (sold by Wako Pure Chemical Industries, Ltd.) as a standard substance of a predetermined concentration, and other glycosyl hesperetin Calculated based on the molecular weight ratio with hesperidin.
- glycosyl hesperetin in which ⁇ -glycosyl hesperidin is ⁇ -glucosyl hesperidin, is the intended effect in the present invention, that is, the effect of improving yellowing of skin and texture, And the effect of improving the skin quality such as dryness of the skin, erythema, irritation, and pruritus is more preferable.
- the preferred content of ⁇ -glucosyl hesperidin in the glycosyl hesperetin is usually 60 to 90%, preferably 70 to 90%, more preferably 75 to 90%, based on the dry solids of the composition. Yes, they are preferable because the above-described effects are more prominent.
- a 1 w / v% aqueous solution was prepared, heated in a sealed container at 100 ° C. for 30 minutes, adjusted to room temperature, put into a cell having a width of 1 cm, and a spectrophotometer the less the difference in absorbance at both wavelengths when measuring the absorbance at a wavelength of 420 nm (OD 420 nm) and wavelength 720nm (OD 720nm) (OD 420nm -OD 720nm) is 0.24, preferably 0.20 or less, more preferably Is 0.17 or less, and more preferably 0 or more and 0.15 or less, the intended effects in the present invention, that is, the skin yellowing and texture-improving action, and skin dryness, erythema, It is preferable because the effect of improving the skin quality such as irritation and pruritus is exhibited more remarkably. Further, it is also superior in that miscellaneous taste / coloring and odor are significantly or
- the calcium, potassium, magnesium, and sodium contents per dry solid of the reducing agent-treated product as measured by high frequency inductively coupled plasma emission spectrometry are the following numerical values.
- the reducing agent-treated product has a significantly different taste, is significantly reduced in coloring and odor, and is excellent in thermal stability. For example, it can be treated at a high temperature of 80 to 100 ° C. Even if it is heated for 30 minutes or more, or the step of containing the reducing agent-treated product or the oral cosmetic containing the same is stored at room temperature or slightly above room temperature for several tens of minutes to several months. In addition, miscellaneous taste / coloration due to the reducing agent-treated product, and further, odor is maintained without change compared to immediately after production, or their increase is effectively suppressed. Furthermore, the reducing agent-treated product has an advantage of good acid resistance and heat resistance.
- the glycosyl hesperetin used in the present invention is a compound having a hesperetin skeleton, whether treated with a reducing agent or not treated with a reducing agent.
- ⁇ -glycosyl hesperidin such as ⁇ -glucosyl hesperidin
- Flavonoids such as nariltin, diosmine, neoponcillin, glucosylnariltin, and (4) trace components such as salts are considered to be produced as secondary products.
- the glycosyl hesperetin may contain hesperetin as long as the intended effects of the present invention are not hindered.
- the glycosyl hesperetin used in the present invention includes hesperetin whose dispersibility in a solvent such as water is improved by a known physical or chemical method or the like within a range in which the intended effect of the present invention is not hindered. It is also possible to mix appropriately.
- the upper limit of the purity of glycosyl hesperetin used in the present invention that is, the content of glycosyl hesperetin per dry solid is usually 99% that can be provided industrially in relatively large quantities, inexpensively and easily, and 98% for providing cheaply. In order to provide it at a lower cost, the content may be as low as 97% or less.
- the lower limit of the glycosyl hesperetin content is usually 90% or more, preferably 93% or more, more preferably 95% or more, and more preferably 97% by mass or more.
- the glycosyl hesperetin used in the present invention when the glycosyl hesperetin is ⁇ -glycosyl hesperidin such as ⁇ -glucosyl hesperidin, the ⁇ -glycosyl hesperidin content per dry solid is 50% or more and less than 100%.
- the glycosyl hesperetin is ⁇ -glycosyl hesperidin such as ⁇ -glucosyl hesperidin
- the ⁇ -glycosyl hesperidin content per dry solid is 50% or more and less than 100%.
- the upper limit of the ⁇ -glucosyl hesperidin content in glycosyl hesperetin used in the present invention is usually relatively large, inexpensive and easily provided industrially when the oral beauty solvent according to the present invention is provided at a lower cost. It may be as low as 90% or less, 85% or less for lower cost, and 80% or less for lower cost.
- the lower limit of the ⁇ -glucosyl hesperidin content is usually preferably 60% or more, 65% or more, or 70% or more for the same reason as the glycosyl hesperetin content.
- the oral beauty agent of the present invention contains various glycosyl hesperetins such as non-reducing agent-treated products and / or reducing agent-treated products as active ingredients.
- glycosyl hesperetins such as non-reducing agent-treated products and / or reducing agent-treated products as active ingredients.
- Glycosyl hesperetin is a so-called beauty to improve skin yellowing, texture, and skin quality that has recently attracted attention because it can effectively improve skin quality such as dryness, erythema, irritation, and pruritus.
- glycosyl hesperetin As food, health food, nutritional functional food, functional health food, food for specified health use, and for other beauty food, health food, nutritional functional food, health functional food, food for specified health use, or food and drink It can be advantageously blended appropriately.
- polyphenols such as resveratrol, quercetin, chlorogenic acid, anthocyanin, curcumin, kaempferol, flavonoids; artichoke leaf extract, tomorrow leaf extract, strawberry seed extract, ginkgo leaf extract Plant extracts such as Wenzhou mandarin orange extract, cassis extract, kiwi seed extract, cranberry extract, acerola extract, amla extract and aronia extract; carotenoids such as astaxanthin and ⁇ -carotene; and plant extracts or compounds having a saccharification reaction inhibitory action When used in combination with one or more ingredients, the effect of improving the yellowing, texture, and skin quality of the skin produced by glycosyl hesperetin
- Examples of the plant extract or compound having an inhibitory action on saccharification reaction include Ibright, Aomi, Akigumi, Agrimony, Agni fruit, Akebi, Acai fruit, Ashwagandha, Asunaro, Acacia catechu, Abemaki, Achacha, Anise, American witch hazel, Aristine, Ikariso , Itadori, Ginkgo biloba, Strawberry, Itohayuri, Itofonori, Inubiwa, Ipe bark, Itohamomiji, Iwatoyuri, Fennel, Witch hazel, Wintergreen, Turmeric, Ume, Vulture, Epimedium brevicornum, Ages, Echinacea ezoe Elder, Elba Mate, Ogashi, Ogaku, Ouren, Milk Thistle, Oats, Obatanekibana, Okajiki, Otome Yuri, Onita Tiger lily, oregano, orange, pumpkin seeds, bonito bark, coconut
- Extracts of seaweed such as hanafunori, fukurofunori, mafunori; extracts of raw coffee beans, sweet potato shochu, agaricus mycelium; and equol, isoflavone, 1,4-anthraquinone, 1-amino-2-hydroxy Methyl anthraquinone, 4-aminophenol, 1,3,5-trihydroxybenzene, kojic acid, 3,4-dihydroxyphenylacetic acid, caffeic acid, ifenprodil, 6-hydroxy-2,5,7,8-tetramethylchroman -2-carboxylic acid, 6-hydroxyindole, 7-hydroxy-4,6-dimethylphthalide ⁇ -lipoic acid, 4-hydroxychalcone, pearl protein hydrolyzate, aminoguanidine, erythrosine sodium, ergothioneine, resveratrol, hydroxystilbenes such as 3,3 ′, 5,5′-tetrahydroxystilbene, oxindole, Car
- the plant extract or compound having a saccharification reaction inhibitory action more preferably used in the present invention includes Ashwagandha, Asunaro, Acacia catechu, Ginkgo biloba, Wintergreen, Aubergine, Orange, Pumpkin seeds, Katsuaba bark, Kusunohagasiwa , Glucosylrutin, Cowberry, Perilla, Buckwheat leaf, Davila rugosa, Dokudami, Himewabamiso, Safflower ragwort, Matatabi, Ryukyuchiku, Ryukyu strawberry, Apple immature fruit, Persimmon leaf, Licorice leaf, Moon peach leaf, Butterberry leaf extract And equol, isoflavone, ifenprodil, pearl protein hydrolyzate, catechol, caffeic acid, and purnin.
- Oral cosmetics of the present invention include troches, liver oil drops, complex vitamins, mouth fresheners, mouth-flavored tablets, oral / tube feeding, oral medicines, various solids, granules, powders, suspensions, pastes It is also optional to use it in various compositions in the form of jelly, jelly or liquid.
- glycosyl hesperetin in the oral cosmetic of the present invention can be adjusted as appropriate depending on the intake frequency of the oral cosmetic and the state of the skin.
- glycosyl hesperetin selected from one or more selected from hesperidin, ⁇ -glycosyl hesperidin, and 7-O- ⁇ -glucosyl hesperetin is all regarded as hesperidin.
- converted to hesperidin When converted to mass (hereinafter referred to simply as “converted to hesperidin” in the present specification), they are more than 10% and less than 100%, preferably more than 15% and less than 100%, more preferably , More than 20% and less than 100%, more preferably more than 30% and less than 100%.
- the ingestion frequency, ingestion amount, and ingestion period of the oral beauty agent of the present invention are selected from hesperidin, ⁇ -glycosyl hesperidin, and one or more glycosyl hesperetins selected from 7-O- ⁇ -glucosyl hesperetin.
- Glycosyl hesperetin is a solid, granular, powder, suspension, paste, etc., such as the aforementioned lozenges, liver oil drops, complex vitamins, mouth fresheners, mouth-flavored tablets, oral / tube feeding, oral medicines, etc.
- a method of blending into various compositions in a jelly-like or liquid form for example, mixing, kneading, mixing, adding, dissolving, dipping, penetrating, spraying, applying, spraying in the process until the composition is completed.
- One or more known methods such as injection can be used as appropriate.
- the oral cosmetic agent of the present invention thus obtained can be used not only in itself but also in various compositions containing the same even when kept or stored at room temperature or slightly above room temperature for several tens of minutes to several months. In addition to the miscellaneous taste and coloration caused by the oral cosmetic agent, the odor is not at all or is remarkably reduced to such an extent that it cannot be perceived.
- the oral beauty agent of the present invention also functions as a highly safe natural antioxidant, stabilizer, quality improver, vitamin P enhancer, etc., and is used as a food, drink, beauty food, health food, and nutritionally functional food. It is also optional to use it in various compositions such as health functional foods, foods for specified health use, feeds and feeds.
- Example 1 Oral intake test>
- Outline For the purpose of investigating the effects of glycosyl hesperetin on the skin, using the powdered glycosyl hesperetin-containing composition obtained in Example 1 described later and prepared without using a predetermined reducing agent, Oral study with 42 working women aged 35 to 55 who have chronic fatigue symptoms known to adversely affect their condition and are concerned about their skin condition such as rough skin
- An intake test was conducted. That is, the subject is orally ingested with a predetermined test sample for a predetermined period, and the instrument is measured for yellowish dullness on the subject's skin (face), and the skin surface texture is visually determined by a doctor. As for, a visual judgment and an inquiry by a doctor were performed, and the influence of the test sample on the skin was evaluated.
- test sample A a capsule tablet type test sample containing glycosyl hesperetin
- test sample B a capsule tablet type test sample
- Test procedure 21 subjects were randomly divided into 21 groups, group A and group B, test sample A as a test sample in group A, and test sample B in group B 2 once a day. Each tablet was ingested orally for 12 weeks. Although the time to ingest the test sample was not specified, each instructed to take it at the same time zone as much as possible.
- the color difference of each subject's cheeks was measured using a color difference meter and evaluated for yellowing of the skin (see “A” below). The texture of the skin surface of the subject's face (see “I” below) was evaluated, and further, the skin quality was evaluated by visual judgment and interview by a doctor (see “C” below).
- each said evaluation was implemented also before the oral intake start (0W) of the test sample, and 6 weeks (6W) after the oral intake start.
- data analysis in group B was performed based on subject data of 20 subjects.
- the a * value represents the degree of redness of the skin
- the “b * value” represents the degree of yellowness of the skin.
- Skin dullness which is a superordinate concept of skin yellowishness, occurs on the entire face or around the eyes and cheeks, and the redness of the skin decreases, yellowing increases, and the glossiness and transparency of the skin decreases. Is a technical term that refers to a state where the brightness decreases due to shadows due to unevenness on the skin surface, etc. It is said that the main cause is yellowing (yellowing).
- the L * value and the b * value is an index of skin brightness
- the b * value is an index of yellowness
- they are independent numerical values that are not linked to each other. It is.
- the degree of skin pigmentation (melanin) can be well divided using the angle when the L * value and the b * value are plotted on a plane as an index.
- the b * value is influenced by factors other than melanin
- the L * value and b * value, including the a * value are numerical values for describing the color, and are specific to melanin.
- glycosyl hesperetin when glycosyl hesperetin is orally ingested by humans, it is thought that glycosyl hesperetin produces hesperetin under the action of in vivo enzymes, and this hesperetin is thought to exert an action to improve or reduce yellowing of skin.
- Glycosyl hesperetin such as hesperidin, 7-O- ⁇ -glucosyl hesperidin, and ⁇ -glycosyl hesperidin, or compositions containing the same are orally ingested by humans, it is judged to have an effect of improving or reducing yellowing of skin.
- glycosyl hesperetin has the effect of effectively improving all of the skin quality such as dryness of the skin, erythema, irritation, and pruritus as well as effectively improving the yellowing and texture of the skin. It is judged.
- a reducing agent treatment was used instead of the glycosyl hesperetin blended in the test sample A used in this test.
- the reducing agent-treated product is significantly or significantly reduced or significantly improved in taste, color, odor, etc., compared to the non-reducing agent-treated product. Therefore, it has the advantage that it can be taken orally without discomfort. That is, the taste of the reducing agent-treated product is significantly reduced as compared with the test sample A used in this test, that is, glycosyl hesperetin (non-reducing agent-treated product) prepared without using a predetermined reducing agent.
- the coloring and the unpleasant odor are remarkably reduced, for example, oral cosmetics containing reducing agent-treated products shown in Examples 2 to 8 described later as active ingredients are continuously administered to humans on a daily basis. Therefore, the product treated with the reducing agent is the most suitable glycosyl for carrying out the present invention. Hesperetin.
- Example 2 Physical properties of glycosyl hesperetin> As glycosyl hesperetin, four powdered glycosyl hesperetins (test samples) prepared in the same manner as those described in Examples 2, 4, 5 and 6 except that no reducing agent was used in the methods described later. 1 to 4) and the method of Example 2, except that 0.1, 0.09, 0.07, or 0.04% by mass of sodium pyrosulfite was used as the reducing agent. Four types of powdered glycosyl hesperetin (test samples 5 to 8) prepared in the above were used.
- Test sample 1 was prepared without using a predetermined reducing agent, and the contents of ⁇ -glucosyl hesperidin, hesperidin, and other components were almost the same as those of powdered glycosyl hesperetin obtained in Example 1. This is equivalent to the powdered glycosyl hesperetin obtained in Example 1.
- GC / MS analysis conditions > GC / MS analyzer: “Claras 680 GC” and “Claras SQ8T” (both manufactured by PerkinElmer) Column: VF-WAXms [30 m (column length) ⁇ 0.25 mm (inner diameter), film thickness 0.25 ⁇ m] (manufactured by AGILENT J & W) Detector: Mass spectrometer Carrier: Helium gas Linear velocity: 35 cm / sec Temperature rising condition: Hold at 40 ° C. for 3 minutes, increase temperature from 40 ° C. to 80 ° C. at a rate of 5 ° C./min, and then to 80 ° C. to 200 ° C.
- the temperature is raised at a rate of 10 ° C./minute, held at 200 ° C. for 7 minutes, heated from 200 ° C. to 220 ° C. at a rate of 10 ° C./minute, and further held at 220 ° C. for 8 minutes.
- Surrogate substance Cyclohexanol Internal standard substance: Henicosan Extraction solvent: Diethyl ether
- the 4-VA content was measured using the following reagents, procedures, and apparatus. In addition, the measurement was performed according to “Notice of Benzene in Soft Drinks” issued on July 28, 2006, by the Food Safety Foundation No. 0728008, the Ministry of Health, Labor and Welfare, Ministry of Health, Labor and Welfare of the Ministry of Health, Labor and Welfare.
- standard solution A 0.0005 mass% 4-VA solution
- standard solution B A mass% 4-VA solution
- each of these test samples 1 to 8 was dissolved in pure water so as to be a 1 w / v% aqueous solution, heated at 100 ° C. for 30 minutes in a sealed container, and then obtained test
- the aqueous solutions of Samples 1 to 8 were each cooled to 20 ° C., and the electric conductivity at 20 ° C. was measured with an electric conductivity meter (trade name “CM-50AT”, manufactured by Toa DKK Corporation).
- the content of the cationic metal element was determined by the following method as a simple method. That is, for each of the test samples 1 to 8, about 0.5 g is precisely weighed in a 50 mL container (trade name “Falcon Tube”, manufactured by Nippon Becton Dickinson Co., Ltd.), heated and dissolved in 20 mL of ultrapure water, and precisely Add 0.54 mL of 60w / w% nitric acid aqueous solution for analysis, heat at 70 ° C. for 14 hours, cool to room temperature, make the total volume to 50 mL with ultrapure water, and use the metal elements under the following analyzer and measurement conditions The content was determined. As a control, only ultrapure water was used.
- Inductively coupled plasma emission spectrometer “CIROS-120” (Spectro) ⁇ Plasma power: 1,400W Plasma gas (Ar): 13.0 L / min Auxiliary gas (Ar): 1.0 L / min Nebulizer gas (Ar): 1.0 L / min Pump operation: 1.0 mL / min Calculation method of metal element content (ppm): ⁇ (measured value of test sample)-(measured value of control) ⁇ x dilution factor
- test samples 1 to 4 were all over 300 ppb, whereas all of test samples 5 to 8 were about 10 ppb. Further, the 4-VA contents of test samples 1 to 4 were all over 40 ppb, whereas the test samples 5 to 8 were all about 2 ppb or less.
- the aqueous solutions of the test samples 1 to 4 (reducing agent non-treated product) was light yellow
- the aqueous solutions of the test samples 5 to 8 (reducing agent-treated product) was clearly lighter than the test samples 1 to 4.
- the degree of coloration by the spectrophotometer was 0.24 or more for all of the aqueous solutions of the test samples 1 to 4, whereas the aqueous solutions of the test samples 5 to 8 were all 0.20 or less. It was low.
- the coloring degree of the test samples 5 to 8 showed a lower value as the amount of the reducing agent used was larger.
- the electrical conductivity of the aqueous solutions of test samples 1 to 4 was about 11 to about 12 ⁇ S / cm and over 10 ⁇ S / cm, whereas the aqueous solutions of test samples 5 to 8 were About 3 to about 7 ⁇ S / cm and less than 10 ⁇ S / cm.
- test samples 5 to 8 As apparent from Table 2, the contents of metal elements (calcium, potassium, magnesium, and sodium) in test samples 5 to 8 are clearly lower than those of test samples 1 to 4, and the results are shown in FIG. It was in good agreement with the measurement results.
- the reducing agent-treated product has a significantly reduced furfural content, and the 4-VA content, coloring degree, electrical conductivity, and metal element content are also significantly reduced. It has been found.
- sample A glycosyl hesperetin
- sample B non-reducing agent-treated product And glycosyl hesperetin
- Coloring determination test 9 healthy males and females (2 females, 7 males) aged 28 to 57 years old were used as panels, and test samples 9 to 11 and Sample B (hereinafter referred to as “control”) were used.
- An evaluation test for coloring was performed. That is, each of the test samples 9 to 11 and the control were dissolved in distilled water at room temperature so as to be a 1 w / w% aqueous solution, and they were visually observed by each panelist, and each panelist compared with the control for each test sample. When it was evaluated that “coloring was reduced”, it was determined as “determination A1”, and when it was evaluated “not colored”, it was determined as “determination B1”.
- the furfural content and the 4-VA content can be used as indicators for distinguishing glycosyl hesperetin in which the miscellaneous taste is significantly reduced and the coloring is significantly reduced. That is, if the furfural content is 200 ppb or less and the 4-VA content is 30 ppb or less, glycosylation with significantly reduced miscellaneous taste and remarkably reduced coloring as compared with the non-reducing agent-treated product. Hesperetin can be obtained.
- Table 2 in the above-described Experiment 2 and Table 3 below summarizes the relationship between the miscellaneous taste of powdered glycosyl hesperetin shown in Examples 1 to 8 described later, the furfural content and the 4-VA content.
- Table 4 the furfural content of test samples 5 to 8 which are reducing agent-treated products and powdered glycosyl hesperetins of Examples 2 to 8 (hereinafter collectively referred to as “reducing agent-treated samples”) is 191 ppb or less.
- the 4-VA content was 28.7 ppb or less, and the miscellaneous taste peculiar to the non-reducing agent-treated product was significantly reduced.
- the furfural content of the powdered glycosyl hesperetin (hereinafter collectively referred to as “reducing agent non-treated sample”) of the test samples 1 to 5 which are non-reducing agent treated products is 308 ppb or more, and the 4-VA content is It was 40.0 ppb or more, and had a miscellaneous taste peculiar to the non-reducing agent-treated product.
- the glycosyl hesperetin treated with the reducing agent is significantly reduced in taste, and the coloring and odor are also significantly reduced compared to the glycosyl hesperetin not treated with the reducing agent. It has been found that human beings can be taken orally on a daily basis safely and easily, and without discomfort.
- ⁇ Experiment 4 Sensory test> (1) Preparation of test sample Of test samples 5 to 8 which are reducing agent-treated products used in Experiment 2, the values of furfural content, coloring degree, electrical conductivity, and metal element content are intermediate. Among the test sample 6 shown and the test samples 1 to 4 which are non-reducing agent-treated products, the test sample 1 having the lowest values of furfural content, coloring degree, electrical conductivity, and metal element content, The sensory test shown in the following (2) was conducted using 8 healthy men and women of 28 to 59 years old (2 women and 6 men) as a panel.
- test sample 1 a reducing agent non-treated product
- test sample 6 a reducing agent treated product
- RO water water that has passed through a reverse osmosis membrane
- test samples 1 and 6 were stored in a sealed container until they were subjected to the following test.
- each of the non-heated test samples 1 and 6 was sealed in a container, heated in a boiling water bath for 30 minutes, and cooled to room temperature to be heated test samples 1 and 6.
- each panelist adjusted the room temperature to the non-heated test samples 1 and 6 (each 10 mL) and the heated test samples 1 and 6 (each 10 mL) obtained in (1). Each was evaluated for a) coloring and (b) odor. Thereafter, each panelist was asked to boil their mouth with white hot water before tasting each test sample, and then (c) bitterness (including astringency, gummy, astringent taste), (d) aftertaste, and (e) Each person was evaluated about the odor at the time of tasting. Evaluation criteria are as shown in Table 5 below.
- the non-heated test sample 6 is used as a control
- the heated test sample 1 is used as a control
- Each panelist was evaluated. The results are shown in Table 6 and Table 7, respectively.
- the evaluation results shown in Tables 6 and 7 include (a) coloring, (b) odor, ( ⁇ ) for the ⁇ -glucosyl hesperidin-containing composition (heated / unheated test sample 1) as a non-reducing agent-treated product.
- the evaluation results of c) bitterness, (d) aftertaste, and (e) odor are not shown, the evaluation results shown in Tables 5 and 6 are based on glycosyl hesperetin, which is a non-reducing agent-treated product. Since the evaluation results of the reducing agent-treated product glycosyl hesperetin are as follows, the evaluation result of the reducing agent-treated product itself is an intermediate value for each evaluation item in terms of the score (five-level evaluation) shown in the evaluation criteria. “3”.
- the non-heated test sample 6, that is, the reducing agent-treated product that has not been heat-treated is (a) colored, (b) odor, (c) bitterness, (d)
- the number of panels evaluated as the highest “1” in the five-level evaluation was 4 out of 8, 4 people, 3 people, 0 people, 3 people, and 4 people, respectively ( 14 people in total).
- the heated test sample 6 shown in the evaluation results of Table 6, that is, the heat-treated reducing agent-treated product is (a) colored, (b) odor, (c) bitter, (d) aftertaste, and (e) odor.
- the number of panels evaluated as the highest “1” in the 5-level evaluation was 4 out of 8, 4, 5, 4, and 4 (total of 24), respectively.
- This result shows that the product treated with the reducing agent is a high-quality glycosyl hesperetin in which not only the bitterness and coloring inherent in the product not treated with the reducing agent but also the odor is effectively reduced.
- the non-heated test sample 6 (glycosyl hesperetin-containing composition that has not been heat-treated) has (a) coloring, (b) odor, (c) bitterness, (d) odor, the number of panels evaluated as “5”, which is the lowest in the 5-level evaluation, and “4”, which is one level higher than the minimum level, was 0 (total 0). It was.
- the heated test sample 6 (heat-treated glycosyl hesperetin-containing composition) was (a) colored, (b) odor, (c) bitter, (d) aftertaste, and ( e) Regarding the odor evaluation items, the number of panels evaluated as “5”, which is the lowest in the 5-level evaluation, and “4”, which is one level higher than the lowest level, was 0 (total 0).
- This result indicates that the product treated with the reducing agent is a high-quality glycosyl hesperetin-containing composition in which not only the taste and color but also the odor is effectively reduced compared to the product not treated with the reducing agent.
- the reducing agent-treated product is (a) colored, (b) odor, (c) bitterness peculiar to the reducing agent non-treated product regardless of heating / non-heating. It was found that all the evaluation items of (d) aftertaste and (e) odor are remarkably excellent, and the difference in superiority and inferiority appears as a more remarkable difference when heated. *
- test samples 5, 7, and 8 shown in “(1) Preparation of test sample” in Experiment 3 were also subjected to “(2) Sensory test” in this experiment 4, and were almost equivalent to the test sample 6. Results were obtained. *
- the reducing agent-treated product has significantly reduced bitterness and aftertaste, i.e., miscellaneous taste, which is unique to the non-reducing agent-treated product, and significantly reduces coloring and odor compared to the non-reducing agent-treated product. Turned out to be. *
- the reducing agent-treated product has significantly reduced bitterness and aftertaste, i.e., miscellaneous taste, which is characteristic of the non-reducing agent-treated product glycosyl hesperetin, and the coloring and odor are remarkable Has been found to be reduced.
- ⁇ Oral beauty agent> As a raw material, 7 parts by mass of dextrin (DE20) is used for 1 part by mass of hesperidin in the same manner as described in Example A-2 of JP-A No. 11-346792, and derived from Bacillus stearothermophilus. Add 20 units of cyclomaltodextrin / glucanotransferase (produced by Hayashibara Co., Ltd.) per gram of dextrin, maintain at pH 6.0 and 75 ° C., and react for 24 hours to obtain a syrup-like glycosyl hesperetin-containing composition.
- DE20 dextrin
- glucanotransferase produced by Hayashibara Co., Ltd.
- the furfural content of this product was 310 ppb, the 4-VA content was 40.0 ppb, the coloring degree was 0.24, and the electric conductivity was about 11 ⁇ S / cm.
- the product contained about 3 ppm, about 0.2 ppm, about 0.4 ppm, and about 1 ppm of calcium, potassium, magnesium, and sodium, respectively, per dry solid.
- DE20 dextrin
- the resulting enzyme reaction solution is heated to inactivate the remaining enzyme, filtered, and the filtrate is applied to a column packed with a porous synthetic adsorbent, trade name “Diaion HP-10” (Mitsubishi Chemical Corporation).
- the liquid was passed at a space velocity (SV) of 2.
- SV space velocity
- ⁇ -glucosyl hesperidin and unreacted hesperidin in the solution adsorbed to the porous synthetic adsorbent, and D-glucose, salts and the like flowed out without being adsorbed.
- purified water is passed through the column, the column is washed, and further passed while increasing the concentration of the aqueous ethanol solution stepwise.
- the fraction containing ⁇ -glucosyl hesperidin is collected, concentrated under reduced pressure, powdered, A pale yellow powdered glycosyl hesperetin-containing composition was obtained in a yield of about 70% based on the mass of raw material hesperidin per dry solid.
- the powdered glycosyl hesperetin-containing composition obtained in this example contained 80.0% by mass of ⁇ -glucosyl hesperidin, 12.3% by mass of hesperidin, and 7.7% by mass of other components.
- This product had a furfural content of 12 ppb, a 4-VA content of 2 ppb, a coloring degree of 0.19, and an electric conductivity of about 6 ⁇ S / cm.
- the product contained about 0.4 ppm, about 0.05 ppm, about 0.1 ppm, and about 0.1 ppm of calcium, potassium, magnesium, and sodium, respectively, per dry solid.
- this product is significantly reduced in taste and color and significantly reduced odor compared to the powdered glycosyl hesperetin-containing composition obtained in Example 1 produced without using a predetermined reducing agent.
- a predetermined reducing agent Even when heated for 30 minutes at a relatively high temperature of 90 to 100 ° C., not only the taste and color, but also the odor was effectively reduced.
- the oral beauty agent of this example is an oral beauty agent that has excellent storage stability and can be taken orally by a human on a daily basis safely and easily without discomfort, and has an action to improve yellowing and texture of skin, and It has excellent advantages that can effectively improve skin quality such as dry skin, erythema, irritation, and pruritus.
- the solution was dissolved with stirring for 30 minutes, neutralized with 0.01 N hydrochloric acid solution, and then immediately Geobacillus stearothermophilus Tc-91 strain (National Institute of Advanced Industrial Science and Technology, Patent Biodeposition Center) No. FERM BP-11273) -derived CGTase was added at 20 units per gram of dextrin, maintained at pH 6.0, 75 ° C., and allowed to react for 24 hours with stirring.
- the resulting enzyme reaction solution is heated to inactivate the remaining enzyme, filtered, and the filtrate is applied to a column packed with a porous synthetic adsorbent, trade name “Diaion HP-10” (Mitsubishi Chemical Corporation).
- the solution was passed through SV2.
- ⁇ -glucosyl hesperidin and unreacted hesperidin in the solution were adsorbed on the porous synthetic adsorbent, and saccharides, salts and the like flowed out without being adsorbed.
- purified water is passed through the column, the column is washed, and further passed while increasing the concentration of the aqueous ethanol solution stepwise.
- the fraction containing ⁇ -glucosyl hesperidin is collected, concentrated under reduced pressure, powdered, A pale yellow powdered glycosyl hesperetin-containing composition was obtained in a yield of about 68% based on the mass of raw material hesperidin per dry solid.
- the powdered glycosyl hesperetin-containing composition obtained in this example contained 79.0% by mass of ⁇ -glucosyl hesperidin, 14.0% by mass of hesperidin, and 7.0% by mass of other components.
- the furfural content of this product was 11 ppb, the 4-VA content was 1.5 ppb, the coloring degree was 0.14, and the electrical conductivity was about 4 ⁇ S / cm. Moreover, this product contained about 0.4 ppm, about 0.06 ppm, about 0.1 ppm, and about 0.1 ppm of calcium, potassium, magnesium, and sodium, respectively, per dry solid.
- this product Compared with the powdered glycosyl hesperetin-containing composition obtained in Example 1 produced without using a predetermined reducing agent, this product has significantly reduced miscellaneous taste and coloring and significantly reduced odor. In addition, even when heated for 30 minutes at a relatively high temperature of 90 to 100 ° C., not only miscellaneous taste and coloring, but also the odor was effectively reduced.
- the oral beauty agent of this example is an oral beauty agent that has excellent storage stability and can be taken orally by a human on a daily basis safely and easily without discomfort, and has an action to improve yellowing and texture of skin, and It has excellent advantages that can effectively improve skin quality such as dry skin, erythema, irritation, and pruritus.
- FERM BP-11273 was added per gram of dextrin and maintained at pH 6.0 and 75 ° C. and reacted for 24 hours, about 72% of hesperidin was found to be It was converted to ⁇ -glycosyl hesperidin.
- the resulting enzyme reaction solution is heated to inactivate the remaining enzyme, filtered, and the filtrate is applied to a column packed with a porous synthetic adsorbent, trade name “Diaion HP-20” (sold by Mitsubishi Chemical Corporation). The solution was passed through SV2.
- ⁇ -glycosyl hesperidin and unreacted hesperidin in the solution were adsorbed on the porous synthetic adsorbent, and D-glucose, salts and the like flowed out without being adsorbed.
- purified water is passed through the column, the column is washed, and further passed while gradually increasing the concentration of the aqueous ethanol solution.
- the fraction containing ⁇ -glycosyl hesperidin is collected, concentrated under reduced pressure, and powdered.
- a pale yellow powdery ⁇ -glycosyl hesperidin-containing composition was obtained in a yield of about 71% based on the mass of raw material hesperidin per dry solid.
- the powdered glycosyl hesperetin-containing composition obtained in this example contained 76.0% by mass of ⁇ -glycosyl hesperidin, 18.5% by mass of hesperidin, and 5.5% by mass of other components.
- the furfural content of this product was 10 ppb, the 4-VA content was 3.0 ppb, the coloring degree was 0.17, and the electric conductivity was about 4 ⁇ S / cm. Further, this product contained about 0.3 ppm, about 0.04 ppm, about 0.1 ppm and about 0.05 ppm of calcium, potassium, magnesium and sodium, respectively, per dry solid.
- this product is significantly reduced in taste and color and significantly reduced odor compared to the powdered glycosyl hesperetin-containing composition obtained in Example 1 produced without using a predetermined reducing agent.
- this product even when heated for 30 minutes at a relatively high temperature of 90 to 100 ° C., it has excellent characteristics in which odor is effectively reduced as well as miscellaneous taste and coloring.
- the oral beauty agent of this example is an oral beauty agent that has excellent storage stability and can be taken orally by a human on a daily basis safely and easily without discomfort, and has an action to improve yellowing and texture of skin, and It has excellent advantages that can effectively improve skin quality such as dry skin, erythema, irritation, and pruritus.
- glucoamylase was added thereto.
- Glucoteam manufactured by Nagase ChemteX Corporation
- the resulting enzyme reaction solution was heated to inactivate the remaining enzyme.
- hesperidinase trade name “Soluble Hesperidinase ⁇ Tanabe> No.
- ⁇ -glucosyl hesperidin, 7-O- ⁇ -glucosyl hesperetin, and unreacted hesperidin in the solution were adsorbed to the porous synthetic adsorbent, and D-glucose, salts, and the like flowed out without being adsorbed.
- purified water is passed through the column, the column is washed, and further passed while increasing the concentration of the aqueous ethanol solution stepwise.
- the ⁇ -glucosyl hesperidin fraction is collected, concentrated under reduced pressure, powdered, and lightly added.
- a yellow powdered glycosyl hesperetin-containing composition was obtained in a yield of about 70% based on the mass of raw material hesperidin per dry solid.
- the powdered glycosyl hesperetin-containing composition obtained in this example is composed of 81.9% by weight of ⁇ -glucosyl hesperidin, 0.5% by weight of hesperidin, 8.9% by weight of 7-O- ⁇ -glucosyl hesperetin, and others. Of 8.7% by mass.
- the furfural content of this product was 9 ppb, the 4-VA content was 2.0 ppb, the coloring degree was 0.16, and the electric conductivity was about 4 ⁇ S / cm.
- the product contained about 0.3 ppm, about 0.03 ppm, about 0.05 ppm, and about 0.05 ppm of calcium, potassium, magnesium, and sodium, respectively, per dry solid.
- this product Compared with the powdered glycosyl hesperetin-containing composition obtained in Example 1 produced without using a predetermined reducing agent, this product has significantly reduced miscellaneous taste and coloring and significantly reduced odor. In addition, even when heated for 30 minutes at a relatively high temperature of 90 to 100 ° C., it has excellent characteristics in which odor is effectively reduced as well as miscellaneous taste and coloring.
- the oral beauty agent of this example is an oral beauty agent that has excellent storage stability and can be taken orally by a human on a daily basis safely and easily without discomfort, and has an action to improve yellowing and texture of skin, and It has excellent advantages that can effectively improve skin quality such as dry skin, erythema, irritation, and pruritus.
- ⁇ Oral beauty agent 50 parts by mass of hesperidin and 1 part by mass of sodium hyposulfite were dissolved in 0.9 part by mass of a 0.25N aqueous sodium hydroxide solution at 80 ° C., 150 parts by mass of DE8 dextrin was added and dissolved, and the pH was adjusted to 9.0. After the adjustment, CGTase derived from Geobacillus stearothermophilus Tc-91 strain (Independent Administrative Institution, National Institute of Advanced Industrial Science and Technology, Patent Biological Depositary Accession No. FERM BP-11273) was added at 15 units per 1 part by mass of dextrin. The solution was adjusted to pH 8.3 while heating up to 0 ° C. and reacted for 6 hours.
- glucoamylase (trade name “Glucoteam”, manufactured by Nagase ChemteX Corporation) was added, and the mixture was further reacted at 55 ° C. for 24 hours.
- the resulting enzyme reaction solution is heated to inactivate the enzyme and applied to a column packed with a medium polarity porous adsorption resin (trade name “Amberlite XAD-7”, manufactured by Rohm & Haas).
- the column was washed with water, and the resin adsorbing component was eluted with an 80 v / v% aqueous ethanol solution. After removing ethanol in the eluate, freeze-drying, ⁇ -glucosyl hesperidin 82.0 wt%, 7-O- ⁇ -glucosyl hesperetin 8.0 wt%, hesperidin 1.0 wt%, and other A powdery glycosyl hesperetin-containing composition containing 9.0% by weight of the component was obtained.
- This product had a furfural content of 10 ppb, a 4-VA content of 1.5 ppb, a coloring degree of 0.15, and an electric conductivity of less than 10 ⁇ S / cm. Moreover, this product contained about 0.4 ppm, about 0.04 ppm, about 0.1 ppm and about 0.2 ppm of calcium, potassium, magnesium and sodium, respectively, per dry solid.
- this product Compared with the powdered glycosyl hesperetin-containing composition obtained in Example 1 produced without using a predetermined reducing agent, this product has significantly reduced miscellaneous taste and coloring and significantly reduced odor. In addition, even when heated for 30 minutes at a relatively high temperature of 90 to 100 ° C., it has excellent characteristics in which odor is effectively reduced as well as miscellaneous taste and coloring.
- the oral beauty agent of this example is an oral beauty agent that has excellent storage stability and can be taken orally by a human on a daily basis safely and easily without discomfort, and has an action to improve yellowing and texture of skin, and It has excellent advantages that can effectively improve skin quality such as dry skin, erythema, irritation, and pruritus.
- This product had a furfural content of 180 ppb, a 4-VA content of 20.0 ppb, a coloring degree of 0.23, and an electric conductivity of less than 10 ⁇ S / cm. Moreover, this product contained about 0.5 ppm, about 0.08 ppm, about 0.1 ppm, and about 0.3 ppm of calcium, potassium, magnesium, and sodium, respectively, per dry solid.
- this product is inferior to the powdered glycosyl hesperetin-containing composition obtained in Examples 2 to 5, the miscellaneous taste is significantly reduced and the coloring and odor are remarkable as compared with the non-reducing agent-treated product.
- the taste and taste are significantly reduced as compared to the non-reducing agent-treated product. Also have excellent properties that are effectively reduced significantly.
- oral beauty agent This product or beauty food containing this, health food, nutritional functional food, health functional food, or food for specified health use (collectively referred to as “oral beauty agent”), and the temperature Even when kept or stored for several tens of minutes to several months at a temperature below or below that range, excellent effects are exhibited in which odor is effectively reduced as well as miscellaneous taste and coloring derived from this product .
- the oral beauty agent is an oral beauty agent that has excellent storage stability and can be taken orally by humans on a daily basis safely and easily without discomfort. Skin quality such as dryness, erythema, irritation, and pruritus can be effectively improved.
- ⁇ Oral beauty agent> In the same manner as in Example 7 except that potassium metasulfite was replaced with sodium hydrogen sulfite, a light yellow powdered glycosyl hesperetin-containing composition was obtained at a yield of about 65% based on the mass of raw material hesperidin per dry solid. Got in.
- the powdered glycosyl hesperetin-containing composition obtained in this example contained 77.2% ⁇ -glucosyl hesperidin, 16.5% hesperidin, and 6.3% other components.
- This product had a furfural content of 191 ppb, a 4-VA content of 28.7 ppb, a coloration degree of 0.23, and an electrical conductivity of less than 10 ⁇ S / cm. Moreover, this product contained about 0.5 ppm, about 0.07 ppm, about 0.09 ppm, and about 0.4 ppm of calcium, potassium, magnesium, and sodium, respectively, per dry solid.
- this product is inferior to the physical properties of the powdered glycosyl hesperetin-containing compositions obtained in Examples 2 to 6, this product has significantly reduced miscellaneous taste compared to the non-reducing agent-treated product.
- coloring and odor are remarkably reduced, and after heating for 30 minutes at a relatively high temperature of 90 to 100 ° C., the miscellaneous taste is significantly reduced as compared with the non-reducing agent-treated product.
- it has excellent characteristics that coloring and odor are also effectively reduced remarkably.
- the product is processed into beauty foods, health foods, functional nutritional foods, functional health foods, or foods for specified health use (hereinafter collectively referred to as “oral beauty agents”) containing the product, and the temperature range. Even when kept or stored for several tens of minutes to several months at a temperature lower than that, excellent effects are exhibited in which the odor is effectively reduced as well as the miscellaneous taste and coloring derived from this product.
- the oral beauty agent is an oral beauty agent that has excellent storage stability and can be taken orally by humans on a daily basis safely and easily without discomfort. Skin quality such as dryness, erythema, irritation, and pruritus can be effectively improved.
- ⁇ Oral beauty agent 10 parts by mass of calcium acetate monohydrate, 50 parts by mass of L-magnesium lactate trihydrate, 57 parts by mass of maltose, 150 parts by mass of the powdered glycosyl hesperetin-containing composition obtained in Example 1, and ⁇ -containing 20% eicosapentaenoic acid 12 parts by mass of cyclodextrin inclusion compound is uniformly mixed and granulated by a granulating machine, and then encapsulated in a gelatin capsule according to a conventional method to contain 300 mg of contents per capsule.
- this product is effective in improving the yellowness and texture of skin by daily daily oral intake of 1 to 10 capsules by humans, as well as dryness of the skin, erythema and irritation. And skin quality such as pruritus can be effectively improved.
- ⁇ Oral beauty agent 10 parts by weight of any of the glycosyl hesperetin-containing compositions obtained in Examples 2 to 8, 0.003 parts by weight of sucralose, 2-glucoside ascorbic acid (trade name “ASCOFRESH” (registered trademark), sold by Hayashibara Co., Ltd.) 0.01 parts by mass and 20 parts by mass of dextrin were mixed with stirring, and 0.5 g each was housed in a stick-shaped light-shielding / moisture-proof packaging container to obtain 7 types of powdered oral cosmetics of the present invention.
- This product is substantially free of miscellaneous taste, coloring and odor, and can be taken orally by humans easily and continuously on a daily basis without discomfort.
- this product is added to various beverages such as water, tea, tea, coffee, and other foods and drinks, orally and continuously ingested by humans on a daily basis, It can improve dullness and texture, and can effectively improve skin quality such as dryness, erythema, irritation and pruritus.
- This product is substantially free of miscellaneous taste, coloration, and off-flavor, and can be taken orally by humans easily and continuously on a daily basis.
- This product is effective in improving skin yellowing and texture by daily oral ingestion of about 30 to 100 mL per day by humans, as well as skin dryness, erythema, irritation and itching. Can effectively improve the skin quality.
- This product is substantially free from miscellaneous taste, coloring, and off-flavor, and can be used as it is or by adding about 1 to 5 mL to drinks such as green tea, tea, coffee, cocoa, and soft drinks.
- drinks such as green tea, tea, coffee, cocoa, and soft drinks.
- skin quality such as dryness of the skin, erythema, irritation and pruritus.
- ⁇ Oral beauty agent> From 1 part by weight of the powdered glycosyl hesperetin-containing composition obtained in Example 1 produced without using a predetermined reducing agent, from sodium sulfite, sodium hyposulfite, potassium pyrosulfite, sodium pyrosulfite, and sulfur dioxide One or two or more selected reducing agents are added in a total amount of 0.0005 parts by mass, uniformly dissolved in 50 parts by mass of purified water, microfiltered, filled into sterile containers, and multiple types of liquid oral cosmetics. An agent was obtained.
- This product is stable in storage, with no substantial taste / coloring or odor increase or change due to the product even after storage for several tens of minutes to several months in a room temperature or relatively high temperature environment. And excellent thermal stability.
- This product is substantially free from miscellaneous taste, coloring, and off-flavor, and can be used as it is or by adding about 1 to 5 mL to drinks such as green tea, tea, coffee, cocoa, and soft drinks.
- drinks such as green tea, tea, coffee, cocoa, and soft drinks.
- skin quality such as dryness of the skin, erythema, irritation and pruritus.
- glycosyl hesperetin used in the oral cosmetic preparation of the present invention in particular, when glycosyl hesperetin prepared using a predetermined reducing agent is used, it is less complex than glycosyl hesperetin prepared without using a predetermined reducing agent.
- the symbol “ ⁇ ” represents the ⁇ -glucosyl hesperidin-containing composition administration group
- the symbol “ ⁇ ” represents the control group
- the symbols “#”, “##”, and “###” are the numerical values of the ⁇ -glucosyl hesperidin-containing composition administration group and the control group, respectively, and the corresponding ⁇ -glucosyl hesperidin.
- P (risk rate) in the statistical hypothesis test is significantly different between the values of the containing composition administration group and the control group at p ⁇ 0.1, p ⁇ 0.05, and p ⁇ 0.01. Show.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
非特許文献2:舛田勇二、『色材』、第76巻、第2号、78乃至83頁、2003年
還元剤処理品の製造原料であるヘスペリジンとしては、従来のグリコシルヘスペレチンの製造において用いられるヘスペリジンのいずれも用いることができ、高純度のヘスペリジンはもとより、比較的低純度のヘスペリジン含有植物由来の抽出物、搾汁液、又はその部分精製物などの1種又は2種以上を適宜組み合わせて用いることもできる。
本願明細書で言う酵素反応とは、前記製造原料としてのヘスペリジンと澱粉部分分解物に糖転移酵素を作用させてα-グリコシルヘスペリジンを生成させる酵素反応を意味する。
本願明細書で言う還元剤処理とは、所定の還元剤を用いて、グリコシルヘスペレチンの雑味と着色(以下、「雑味・着色」と略記する場合がある。)、更には臭気を有意ないしは顕著に低減させるための処理を意味し、後述する還元剤を、(ア)ヘスペリジン及び澱粉部分分解物を含有する水溶液を調製する工程、(イ)得られた水溶液に糖転移酵素を作用させα-グルコシルヘスペリジンを含むグリコシルヘスペレチン含有組成物を生成させる工程、及び(ウ)生成したグリコシルヘスペレチン含有組成物を採取する工程の1又は2以上の工程で用いるか、前記(ア)乃至(ウ)の1又は2以上の工程の前の始発原料及び/又は前記工程後の結果物に、その所定量を添加することを意味する。
斯くして得られる酵素反応溶液は、これをそのまま、本発明で好適に用いられる雑味等が低減されたグリコシルヘスペレチンとすることができる。しかし、通常、酵素反応溶液は、斯界において公知の分別方法、濾過方法、多孔性合成樹脂等を用いる精製方法、濃縮方法、噴霧方法、乾燥方法などの1種又は2種以上の手段を適宜組み合わせて、液状、固状、粉末状などの還元剤処理品とする。
(2)還元剤処理品の製造工程において、還元剤が、雑味の原因物質が生成するのを低減ないしは抑制するか、生成した雑味の原因物質をマスク、分解ないしは修飾し、雑味が有意に低減されたグリコシルヘスペレチンが得られる。
(3)前記(1)及び(2)に示す雑味の原因物質が還元剤により修飾を受け、多孔性合成吸着剤などによる精製工程でグリコシルヘスペレチンと分離し易くなり、その結果、雑味が有意に低減された還元剤処理品が得られる。
HPLC装置:『LC-20AD』(株式会社島津製作所製)
デガッサー:『DGU-20A3』(株式会社島津製作所製)
カラム:『CAPCELL PAK C18 UG 120』
(株式会社資生堂製)
サンプル注入量:10μ1
溶離液:水/アセトニトリル/酢酸(80/20/0.01(容積比))
流 速:0.7m1/分
温 度:40℃
検 出:UV検出器『SPD-20A』 (株式会社島津製作所製)
測定波長:280nm
データ処理装置:『クロマトパックC-R7A』 (株式会社島津製作所製)
(1)ヘスペリジン含量:HPLCにて分析し、そのピーク面積と、所定濃度の標準物質の試薬ヘスペリジン(和光純薬工業株式会社販売)のピーク面積との比に基づいて算出する。
(2)α-グルコシルヘスペリジン含量:HPLCにて分析し、そのピーク面積と、所定濃度の標準物質の試薬ヘスペリジン(和光純薬工業株式会社販売)のピーク面積との比と、α-グリコシルヘスペリジンとヘスペリジンの分子量比に基づいて算出する。
(3)7-O-β-グルコシルヘスペレチン含量:HPLCにて分析し、そのピーク面積と、所定濃度の標準物質の試薬ヘスペリジン(和光純薬工業株式会社販売)のピーク面積との比と、7-O-β-グルコシルヘスペレチンとヘスペリジンの分子量比に基づいて算出する。
(4)その他のグリコシルヘスペレチン含量:HPLCにて分析し、そのピーク面積と、所定濃度の標準物質の試薬ヘスペリジン(和光純薬工業株式会社販売)のピーク面積との比と、その他のグリコシルヘスペレチンとヘスペリジンとの分子量比に基づいて算出する。
<実験1:経口摂取試験>
(1)概要
グリコシルヘスペレチンが肌に及ぼす影響について調べる目的で、所定の還元剤を用いないで調製された、後述する実施例1で得た粉末状グリコシルヘスペレチン含有組成物を用いて、肌質の状態に悪影響を及ぼすことが知られている慢性的な疲労症状を有し、肌荒れなどの肌質の状態が気になっている、35歳以上55歳未満の勤労女性42名を被験者とする経口摂取試験を行った。すなわち、被験者に所定の被験試料を所定の期間、経口摂取させ、被験者の肌(顔)の黄くすみについて機器測定するとともに、皮膚表面のキメについては、医師による目視判定を行い、また、肌質については医師による目視判定と問診とを行い、被験試料が肌に及ぼす影響について評価した。
経口摂取試験で用いる被験試料として、公知のハードゼラチンカプセルの製造方法(特公平2-51528号公報参照)に準じて、下記表1に示すハードゼラチンカプセル(サイズ#1、カプスゲル・ジャパン社製)にデキストリンを除く他の原料を封入し、グリコシルヘスペレチンを含有するカプセル錠剤タイプの被験試料(以下、「被験試料A」と言う。)を調製するとともに、対照として、前記ハードゼラチンカプセルにグリコシルヘスペレチン以外の他の原料を封入し、グリコシルヘスペレチン不含有のカプセル錠剤タイプの被験試料(以下、「被験試料B」と言う。)を調製した。
被験者42名を無作為に21名ずつ、A群とB群とに分け、A群には被験試料として被験試料Aを、B群には被験試料Bを1日当たり一回2錠、12週間に亘って各自経口摂取させた。被験試料を摂取する時間は特に指定しなかったが、各自なるべく同じ時間帯に摂取するよう指示した。12週間に亘る経口摂取試験終了後、直ちに、色差計を用いて各被験者の頬の色差測定をし、肌の黄くすみについて評価するとともに(下記「ア」参照)、医師による目視判定により、各被験者の顔の皮膚表面のキメ(下記「イ」参照)について評価し、更に、医師による目視判定と問診により、肌質について評価した(下記「ウ」参照)。なお、前記各評価は、被験試料の経口摂取開始前(0W)、及び経口摂取開始後6週間目(6W)にも実施した。なお、B群の被験者1名は、試験途中で試験継続を辞退したことから、B群のデータ解析は、20名の被験者データを元に行った。
・測定項目:L*a*b*表示系に基づく肌の色差測定を行った。
・使用機器:色差計として、『コニカミノルタ分光測色計 CM-2600d』、コニカミノルタ社製を用いて、皮膚色を解析した。
・測定箇所:左顔、耳朶下と唇端とを結んだ中心部を測定した(但し、測定箇所に黒子や炎症がある場合には、それらを避けて測定した)。
・色差測定における解析対象:L*a*b*表示系における座標軸であるa*(赤み)及びb*(黄み)の値。
a*値は肌の赤みの程度を表わし、「b*値」は肌の黄みの程度を表わす。なお、肌の黄くすみの上位概念である肌のくすみは、顔全体又は目の周りや頬などの部位に生じ、肌の赤みが減少して黄みが増し、肌のつやや透明感が減少したり、皮膚表面の凹凸などによる影によって明度が低下して暗く見える状態を指す技術用語であるのに対し、黄くすみは、肌の深部にある真皮の蛋白質が過酸化物質などによって変性(カルボニル化)し、黄色に変色(黄食化)することが主たる原因ではないかと言われている。これらの技術的背景に基づき、本試験では、L*a*b*表示系における座標軸であるa*値及びb*値を測定し、これらを肌の黄色くすみを評価する指標とした。
・採用値:測定値(n=3)を平均した。
・評価部位:評価は、左顔、耳朶下と唇端とを結んだ中心部を中心とする部位について行った。
・評価方法:下記判定基準に基づき、医師が補助光とマイクロスコープを用い、評価部位を目視判定してスコア値を求めた。
<判定基準>
・良好:スコア値は、2
・やや良好:スコア値は、1
・普通:スコア値は、0
・やや不良:スコア値は、-1
・不良:スコア値は、-2
・評価部位:顔全体の皮膚
・評価方法:下記判定基準に基づき、医師が補助光とマイクロスコープを用い、評価部位を目視判定するとともに、各被験者に問診してスコア値を求めた。
<判定基準>
・なし:症状が認められない(スコア値は、0)
・軽微:わずかに症状が見られる(スコア値は、1)
・軽度:少し症状が見られる(スコア値は、2)
・中程度:明らかな症状が見られる(スコア値は、3)
・重度:著しい症状が見られる(スコア値は、4)
(4-1)色差測定の結果と考察
被験試料A、Bをそれぞれ経口摂取させたA群及びB群の各被験者につき、前記(3)の「ア」に示す色差測定における解析対象を指標に色差測定し、得られた測定値を元に平均値±標準誤差を求め、それら数値に基づいて作成した図をそれぞれ図1及び図2として示す。
被験者の肌のキメについて、医師が補助光とマイクロスコープを用いて目視評価し、得られたスコア値の経時変化を図3に示す。図3から明らかなとおり、被験試料Bを経口摂取させたB群においては、経口摂取開始後6週間目(6W)の時点では殆ど変化がなく、経口摂取開始後12週間目(12W)の時点でスコア値はやや増加した程度であったのに対し、被験試料Aを経口摂取したA群では、スコア値は経時的に増加し、経口摂取開始後12週間目(12W)の時点では、スコア値の有意な増加を認めた。更に、医師の所見によれば、肌のキメの指標としての皮丘、皮溝の評価を含む肌の総合評価において、被験試料Bを経口摂取したB群においては効果が認められなかったのに対し、被験試料Aを経口摂取したA群では、経口摂取開始前(0W)と比べ、経口摂取開始後12週間目(12W)の時点においては、皮丘の大きさや高さがより均一になっているとともに、皮溝が細かく浅くなっている傾向が認められ、肌のキメ改善作用が認められた。
被験者の顔全体の肌質の状態について、医師が補助光とマイクロスコープを用いて目視評価するとともに、各被験者に問診をして得られたスコア値の経時変化を図4乃至図7に示す。これらの図から明らかなとおり、被験試料Bを経口摂取させたB群の被験者と比べ、被験試料Aを経口摂取させたA群の被験者においては、肌の乾燥、紅斑、刺激感、及び掻痒感のいずれについても、経口摂取開始前(0W)と比べ、経口摂取開始後6週間目(6W)及び12週間目(12W)の時点で有意な改善が認められたことから、被験試料Aは、肌の乾燥、紅斑、刺激感、及び掻痒感のいずれをも効果的に改善する作用を有することが判明した。
グリコシルヘスペレチンとして、後述する実施例2、4、5及び6の方法において、還元剤を用いない以外はそれら実施例に記載された方法と同様にして調製した4種類の粉末状グリコシルヘスペレチン(被験試料1乃至4)と、実施例2の方法において、還元剤としてピロ亜硫酸ナトリウムを0.1、0.09、0.07又は0.04質量%用いた以外は、実施例2の方法と同様にして調製した4種類の粉末状グリコシルヘスペレチン(被験試料5乃至8)を用いた。なお、被験試料1は、所定の還元剤を用いないで調製されたもので、α-グルコシルヘスペリジン、ヘスペリジン、及びその他の成分含量は実施例1で得た粉末状グリコシルヘスペレチンのそれとほぼ同等であり、実施例1で得た粉末状グリコシルヘスペレチンと同等品である。
被験試料1乃至8のそれぞれにつき、下記手順及び装置を用いてフルフラール含量を求めた。
(ア)50mL容共栓付三角フラスコに被験試料としてのグリコシルヘスペレチンを0.5g採取する。
(イ)次いで、脱イオン水を5.0mL加えグリコシルヘスペレチンを溶解し、サロゲート物質(分析に際し、被験試料の回収率を調べるための指標)として、濃度0.0025%のシクロヘキサノールを20μLを加える。
(ウ)更に、塩化ナトリウムを1.5g加え溶解し、ジエチルエーテルを3mL加え、700rpmで10分間攪拌する。
(エ)全量を分液漏斗に移し取り、10分間静置した後、ジエチルエーテル相を回収し、硫酸ナトリウムにて脱水後、窒素気流下、約200μLとなるまで濃縮する。
(オ)濃縮液1μLを採取し、GC/MS分析装置に供する。
(カ)対照として、グリコシルヘスペレチンに代えて試薬級フルフラールを用いた以外は被験試料と同様、(ア)乃至(オ)の処理を行う。
GC/MS分析装置:『Clarus 680 GC』及び『Clarus SQ8T』(いずれもパーキンエルマー社製)
カラム:VF-WAXms[30m(カラム長)×0.25mm(内径)、膜厚0.25μm](AGILENT J&W社製)
検出器:質量分析器
キャリアー:ヘリウムガス
線速度35cm/秒
昇温条件:40℃で3分間保持し、40℃~80℃まで5℃/分の割合で昇温し、80℃~200℃まで10℃/分の割合で昇温し、200℃で7分間保持し、200℃~220℃まで10℃/分の割合で昇温し、更に、220℃で8分間保持する。
サロゲート物質:シクロヘキサノール
内部標準物質:ヘンエイコサン
抽出溶媒:ジエチルエーテル
GC/MS分析法で得られた、対照の試薬特級フルフラール(和光純薬工業株式会社製)についての測定データを元に検量曲線を作成し、これに基づいて、被験試料のフルフラール含量を求めた。
被験試料1乃至8のそれぞれにつき、下記試薬、手順、及び装置を用いて4-VA含量を測定した。なお、その測定は、平成18年7月28日付、食安基発第0728008号厚生労働省医薬食品局食品安全部基準審査課長通知『清涼飲料水中のベンゼンについて』に準じて行った。
(ア)塩化ナトリウム(水質試験用、和光純薬工業株式会社販売)
(イ)シクロヘキサノール標準原液の調製
シクロヘキサノール(試薬一級、片山化学工業株式会社販売)をメタノール(局方一般試験法用)に溶解して0.01質量%シクロヘキサノール溶液(以下、「シクロヘキサノール標準原液」と言う。)を調製した。
(ウ)内部標準液前記シクロヘキサノール標準原液とメタノールを用いて、0.0004質量%シクロヘキサノール溶液(以下、「内部標準液1」と言う。)及び0.00004質量%シクロヘキサノール溶液(以下、「内部標準液2」と言う。)を調製した。
(エ)標準原液の調製
4-VA(和光純薬工業株式会社販売)をメタノールに溶解し、0.0005質量%4-VA溶液(以下、「標準液A」と言う。)及び0.00005質量%4-VA溶液(以下、「標準液B」と言う。)をそれぞれ調製した。
(オ)検量線作成用標準原液の調製
前記標準液A、B、前記内部標準液1、及びメタノールを用いて、4-VA濃度が0.05、0.1、0.2、0.5又は1.0μg/mLである5種類の検量線作成用混合標準原液を調製した。
(カ)検量線作成用標準液の調製
20mL容ヘッドスペースバイアル5本にそれぞれ超純水を10mL加え、更に前記5種類の検量線作成用混合標準原液のいずれかを10μL加え、更に塩化ナトリウム3.0gを添加し、直ちに密栓し、撹拌溶解し、5種類の検量線作成用標準液を調製した。
20mL容ヘッドスペースバイアル8本に被験試料1乃至8のいずれかを乾燥固形物換算で0.20g精秤し、これに超純水を加え全量を10.0gとし、撹拌溶解した。得られた水溶液に前記内部標準液2を10μL加え、更に塩化ナトリウムを3.0g添加し、直ちに密栓し、撹拌溶解し、被験試料1乃至8のいずれかを含む8種類の被験試料を調製した。
(ア)測定条件
<GC/MS分析条件>
・GC/MS分析装置:『Clarus SQ8T GC/MS』(パーキンエルマー社製)
・ヘッドスペースサンプラー:『TurboMatrix Trap 40』パーキンエルマー社製)
・カラム:VF-WAXms[カラム長30m×内径0.25mm、膜厚0.25μm)(AGILENT J&W社製)
・検出器:質量分析器
・キャリアー:ヘリウムガス
・線速度:35cm/秒
・カラム注入口温度:200℃
・昇温条件:40℃で3分間保持し、40℃~80℃まで5℃/分の割合で昇温し、80℃~200℃まで10℃/分の割合で昇温し、200℃で7分間保持し、200℃~220℃まで10℃/分の割合で昇温し、更に、220℃で8分間保持する。
・バイアルオーブン温度:60℃
・ニードル温度:140℃
・トランスファーライン温度:205℃
・バイアル加熱時間:30分間
<検出法>
・イオン化[Electron
Impact(EI)]法
・SIM選択イオン(Selected Ion Monitoring)
m/z 134, 119 (4-VA)
m/z 82, 57 [シクロヘキサノール(試薬一級、片山化学工業株式会社販売)]
前記5種類の検量線作成用標準液と前記8種類の被験試料における4-VAと内部標準(シクロヘキサノール)のピーク高さ比と、別途作成しておいた4-VAの検量線とに基づき、前記被験試料における4-VA濃度を求め、それに基づいて被験試料1乃至8における4-VA含量を算出した。
被験試料1乃至8の水溶液それぞれにつき、色調を肉眼観察するとともに、下記手順により、着色度を求めた。すなわち、被験試料1乃至8のそれぞれにつき、1w/w%水溶液とし、その40mLを密閉容器(50mL容)中で100℃で30分間加熱した後、27℃とし、幅1cmのセルに入れ、分光光度計(商品名『UV-2600』、株式会社島津製作所製)により、波長420nm(OD420nm)及び波長720nm(OD720nm)における吸光度を測定し、両波長における吸光度の差(OD420nm-OD720nm)を求め、その値を着色度とした。なお、吸光度差の数値が小さいほど、着色度が低いことを意味する。
次いで、これら被験試料1乃至8のそれぞれにつき、1w/v%水溶液となるように純水に溶解し、密閉容器中で100℃で30分間加熱した後、得られた被験試料1乃至8の水溶液をそれぞれ20℃に冷却し、20℃での電気伝導度を電気伝導度計(商品名『CM-50AT』、東亜ディーケーケー株式会社製)により測定した。
イオン性化合物を定量することは容易ではないので、簡便法として、下記手法により、陽イオン金属元素の含量を求めた。すなわち、被験試料1乃至8のそれぞれにつき、約0.5gを50mL容器(商品名『ファルコンチューブ』、日本ベクトンディッキンソン株式会社製)に精秤し、超純水20mLに加熱溶解し、これに精密分析用の60w/w%硝酸水溶液を0.54mL添加し、70℃で14時間加熱し、室温まで冷却した後、超純水にて全量を50mLとし、下記分析装置と測定条件下で金属元素含量を求めた。なお、対照は超純水のみを用いた。
・誘導結合プラズマ発光分光分析装置:『CIROS-120』(Spectro社製)
・プラズマ電力:1,400W
・プラズマガス(Ar):13.0 L/分
・補助ガス(Ar):1.0 L/分
・ネブライザーガス(Ar):1.0 L/分
・ポンプ動作:1.0 mL/分
・金属元素含量(ppm)の算出方法:{(被験試料の測定値)-(対照の測定値)}×希釈倍率
グリコシルヘスペレチンの雑味及び着色と、フルフラール及び4-VAの含量との関係を調べる目的で下記の試験を行った。
後述する実施例5の方法及び実施例1の方法に準じて、還元剤処理品であるグリコシルヘスペレチン(以下、「試料A」と言う。)と、還元剤非処理品であるグリコシルヘスペレチン(以下、「試料B」と言う。)とをそれぞれ調製した。次いで、便宜上、試料A、Bを適宜割合で配合し、フルフラール含量が段階的に異なる、表3に示す3種類のグリコシルヘスペレチン試料(以下、「被験試料9乃至11」と言う。)を調製した。
実験2の「(1)フルフラールの含量」及び「(2)4-VAの含量」に示す測定方法にしたがって、被験試料9乃至11のフルフラール含量と4-VA含量とをそれぞれ測定した。
28乃至57歳の健常な男女9人(女性2人、男性7人)をパネルとし、被験試料9乃至11及び試料B(以下、「対照」と言う。)を用いて着色についての評価試験を行った。すなわち、被験試料9乃至11及び対照をそれぞれ蒸留水に1w/w%水溶液となるように室温で溶解し、それらを各パネリストに肉眼観察させ、各パネリストが各被験試料につき、対照と比べ、「着色が低減されている」と評価した場合には「判定A1」、「着色が低減されていない」と評価した場合には「判定B1」と判定させ、その結果を表3に示した。
前記男女9人をパネルとし、被験試料9乃至11及び対照の雑味について官能試験を行った。すなわち、被験試料9乃至11及び対照をそれぞれ蒸留水に1w/w%水溶液となるように室温で溶解し、それらを各パネリストに試飲させ、各パネリストが、各被験試料につき対照と比べ、「雑味が改善されている」と評価した場合には「判定A2」と判定させ、「雑味が改善されていない」と評価した場合には「判定B2」と判定させ、その結果を表3に示した。
(1)被験試料の調製
実験2で用いた、還元剤処理品である被験試料5乃至8の内、フルフラール含量、着色度、電気伝導度、及び金属元素含量のそれぞれが中間に位置する値を示した被験試料6と、還元剤非処理品である被験試料1乃至4の内、フルフラール含量、着色度、電気伝導度、及び金属元素含量が最も低値を示した被験試料1を用いて、28乃至59歳の健常な男女8名(女性2名、男性6名)をパネルとする下記(2)に示す官能試験を行った。すなわち、還元剤非処理品(被験試料1)と還元剤処理品(被験試料6)をそれぞれ1w/v%水溶液となるように室温でRO水(逆浸透膜を通した水)に溶解し、非加熱被験試料1、6とし、これらを下記試験に供するまで密閉容器中にて保管した。また、非加熱被験試料1、6をそれぞれ、容器に入れ密閉し、沸騰水浴中で30分間加熱し、室温まで冷却したものを加熱被験試料1、6とした。
各パネリストに、室温に調整した、前記(1)で得た非加熱被験試料1、6(各10mL)及び加熱被験試料1、6(各10mL)について、試飲前に、(a)着色と(b)臭気とを各自に評価させた。その後、各パネリストには、各被験試料を試飲する前に白湯で口を漱がせた後、(c)苦味(渋み、えぐみ、収斂味を含む)、(d)後味、及び(e)試飲時の臭気について各自に評価させた。評価基準は下記表5に示すとおりである。なお、非加熱被験試料6に対しては、非加熱被験試料1を対照とし、加熱被験試料6に対しては、加熱被験試料1を対照とし、前記(a)乃至(e)の各評価項目につき、各パネリストに評価させた。結果はそれぞれ、表6及び表7に示す。
原料として、特開平11-346792号公報の実施例A-2に記載された方法と同様にして、ヘスペリジン1質量部に対しデキストリン(DE20)を7質量部用い、バチルス・ステアロサーモフィルス由来のシクロマルトデキストリン・グルカノトランスフェラーゼ(株式会社林原製)をデキストリングラム当り20単位加え、pH6.0、75℃に維持し、24時間反応させ、シラップ状グリコシルヘスペレチン含有組成物を得、これにグルコアミラーゼ(商品名『グルコチーム』、ナガセケムテックス株式会社製)をグリコシルヘスペレチン含有組成物の乾燥固形物グラム当り100単位加え、50℃、5時間反応させた。次いで、得られたシラップ状グリコシルヘスペレチン含有組成物を減圧濃縮し、粉末化して、粉末状グリコシルヘスペレチン含有組成物を乾燥固形物当り、原料のヘスペリジン質量に対し約60%の収率で得た。本品は、α-グルコシルヘスペリジン77.0質量%、ヘスペリジン15.5質量%、その他の成分を7.5質量%含有していた。
1規定水酸化ナトリウム水溶液4質量部を80℃に加温し、この温度を維持しつつ、ヘスペリジン1質量部及びデキストリン(DE20)7質量部を加え、30分間撹拌しつつ溶解させ、pHを9.0とし、これにジオバチルス・ステアロサーモフィラス Tc-91株(独立行政法人産業技術総合研究所、特許生物寄託センター 受託番号FERM BP-11273、寄託日:1973年7月30日)由来のCGTaseをデキストリングラム当り30単位加え、pH6.9、50℃に維持しつつ18時間反応させ、ヘスペリジンの約70%をα-グリコシルヘスペリジンに変換させた。次いで、得られた酵素反応液に対し、還元剤としてのピロ亜硫酸ナトリウムを0.05質量%添加し、100℃で30分間加熱するともに、残存する酵素を加熱失活させた後、グルコアミラーゼ(商品名『グルコチーム』、ナガセケムテックス株式会社製)を酵素反応液の固形分グラム当り100単位加え、pH5.0、55℃に維持しつつ5時間反応させ、α-グルコシルヘスペリジンを生成させた。得られた酵素反応液を加熱して残存する酵素を失活させ、濾過し、濾液を多孔性合成吸着剤、商品名『ダイヤイオンHP-10』(三菱化学株式会社販売)を充填したカラムに空間速度(SV)2で通液した。その結果、溶液中のα-グルコシルヘスペリジンと未反応ヘスペリジンとが多孔性合成吸着剤に吸着し、D-グルコース、塩類などは吸着することなく流出した。次いで、カラムに精製水を通液し、カラムを洗浄した後、エタノール水溶液濃度を段階的に高めながら更に通液し、α-グルコシルヘスペリジン含有画分を採取し、減圧濃縮し、粉末化して、淡黄色の粉末状グリコシルヘスペレチン含有組成物を乾燥固形物当り原料のヘスペリジン質量に対して約70%の収率で得た。なお、本例で得られた粉末状グリコシルヘスペレチン含有組成物は、α-グルコシルヘスペリジンを80.0質量%、ヘスペリジンを12.3質量%、その他の成分を7.7質量%含有していた。
1規定水酸化ナトリウム水溶液4質量部を80℃に加温し、この温度を維持しつつ、これにヘスペリジン1質量部、デキストリン(DE10)4質量部、及び亜硫酸ナトリウム0.06質量部を順次添加し、30分間撹拌しつつ溶解させ、0.01規定塩酸溶液にて中和した後、直ちにジオバチルス・ステアロサーモフィラス Tc-91株(独立行政法人産業技術総合研究所、特許生物寄託センター 受託番号FERM BP-11273)由来のCGTaseをデキストリングラム当り20単位加え、pH6.0、75℃に維持し、攪拌しつつ、24時間反応させた。得られた酵素反応液をサンプリングして、高速液体クロマトグラフィーで分析したところ、ヘスペリジンの約69%が、α-グリコシルヘスペリジンに変換していた。次いで、得られた酵素反応液に還元剤としてピロ亜硫酸ナトリウムを0.03質量%となるように添加し、90℃で120分間加熱した後、グルコアミラーゼ(商品名『グルコチーム』、ナガセケムテックス株式会社製)を当該中間生成物グラム当り50単位加え、pH5.0、55℃に維持しつつ10時間反応させ、α-グルコシルヘスペリジンを生成させた。得られた酵素反応液を加熱して残存する酵素を失活させ、濾過し、濾液を多孔性合成吸着剤、商品名『ダイヤイオンHP-10』(三菱化学株式会社販売)を充填したカラムにSV2で通液した。その結果、溶液中のα-グルコシルヘスペリジンと未反応ヘスペリジンとが多孔性合成吸着剤に吸着し、糖類や塩類などは吸着することなく流出した。次いで、カラムに精製水を通液し、カラムを洗浄した後、エタノール水溶液濃度を段階的に高めながら更に通液し、α-グルコシルヘスペリジン含有画分を採取し、減圧濃縮し、粉末化して、淡黄色の粉末状グリコシルヘスペレチン含有組成物を乾燥固形物当り原料のヘスペリジン質量に対して約68%の収率で得た。なお、本例で得られた粉末状グリコシルヘスペレチン含有組成物は、α-グルコシルヘスペリジン79.0質量%、ヘスペリジン14.0質量%、その他の成分を7.0質量%含有していた。
1規定水酸化ナトリウム水溶液4質量部を80℃に加温し、この温度を維持しつつ、これに還元剤として亜硫酸ナトリウム0.1質量部、ヘスペリジン1質量部、及びデキストリン(DE10)4質量部を順次添加し、30分間撹拌しつつ溶解し、これに0.01規定塩酸溶液を加えて中和した後、直ちにジオバチルス・ステアロサーモフィラス Tc-91株(独立行政法人産業技術総合研究所、特許生物寄託センター 受託番号FERM BP-11273)由来のCGTaseをデキストリングラム当り20単位加え、pH6.0、75℃に維持し、攪拌しつつ、24時間反応させたところ、ヘスペリジンの約72%がα-グリコシルヘスペリジンに変換していた。得られた酵素反応液を加熱して残存する酵素を失活させ、濾過し、濾液を多孔性合成吸着剤、商品名『ダイヤイオンHP-20』(三菱化学株式会社販売)を充填したカラムにSV2で通液した。その結果、溶液中のα-グリコシルヘスペリジンと未反応ヘスペリジンとが多孔性合成吸着剤に吸着し、D-グルコース、塩類などは吸着することなく流出した。次いで、カラムに精製水を通液し、カラムを洗浄した後、エタノール水溶液濃度を段階的に高めながら更に通液し、α-グリコシルヘスペリジン含有画分を採取し、減圧濃縮し、粉末化して、淡黄色の粉末状α-グリコシルヘスペリジン含有組成物を乾燥固形物当り、原料のヘスペリジン質量に対して約71%の収率で得た。なお、本例で得られた粉末状グリコシルヘスペレチン含有組成物は、α-グリコシルヘスペリジン76.0質量%、ヘスペリジン18.5質量%、その他の成分を5.5質量%含有していた。
ヘスペリジン1質量部、デキストリン(DE8)10質量部、及び還元剤としてピロ亜硫酸ナトリウム0.05質量部を水500質量部に添加し、pH9.5、90℃で70分間加熱し、次いで、ジオバチルス・ステアロサーモフィラス Tc-91株(独立行政法人産業技術総合研究所、特許生物寄託センター 受託番号FERM BP-11273)由来のCGTaseをデキストリングラム当り30単位加え、pH8.2、65℃に維持し、攪拌しつつ、40時間保持しつつ、この酵素反応が終了する直前に、ピロ亜硫酸ナトリウム0.05質量部を添加し、85℃で加熱し、酵素を失活させた後、これにグルコアミラーゼ(商品名『グルコチーム』、ナガセケムテックス株式会社製)を酵素反応液固形物グラム当り100単位加え、pH5.0、55℃に維持しつつ5時間反応させ、α-グルコシルヘスペリジンを生成させた。得られた酵素反応液を加熱して残存する酵素を失活させた。次いで、得られた酵素反応液に、α-L-ラムノシダーゼとしてヘスペリジナーゼ(商名『可溶性ヘスペリジナーゼ<タナベ>2号』、田辺製薬製)を0.5質量部を添加し、pH4に調整し、55℃で24時間反応させ、得られた酵素反応液にピロ亜硫酸ナトリウム0.01質量部を添加し、加熱して酵素を失活させた後、濾過し、濾液を多孔性合成吸着剤、商品名『ダイヤイオンHP-10』(三菱化学株式会社販売)を充填したカラムにSV2で通液した。その結果、溶液中のα-グルコシルヘスペリジン、7-O-β-グルコシルヘスペレチン、及び未反応ヘスペリジンとが多孔性合成吸着剤に吸着し、D-グルコース、塩類などは吸着することなく流出した。次いで、カラムに精製水を通液し、カラムを洗浄した後、エタノール水溶液濃度を段階的に高めながら更に通液し、α-グルコシルヘスペリジン画分を採取し、減圧濃縮し、粉末化して、淡黄色の粉末状グリコシルヘスペレチン含有組成物を乾燥固形物当り原料のヘスペリジン質量に対して約70%の収率で得た。なお、本例で得られた粉末状グリコシルヘスペレチン含有組成物は、α-グルコシルヘスペリジン81.9質量%、ヘスペリジン0.5質量%、7-O-β-グルコシルヘスペレチン8.9質量%、及びその他の成分を8.7質量%含有していた。
ヘスペリジン50質量部と次亜硫酸ナトリウム1質量部とを0.25規定水酸化ナトリウム水溶液0.9質量部に80℃で加熱溶解し、DE8のデキストリン150質量部を添加し溶解し、pH9.0に調整した後、ジオバチルス・ステアロサーモフィラス Tc-91株(独立行政法人産業技術総合研究所、特許生物寄託センター 受託番号FERM BP-11273)由来のCGTaseをデキストリン1質量部当たり15単位加え、60℃まで加温しながらpH8.3に調整し、6時間反応させた。その後、pH7.0に調整し、68℃に加温して40時間反応させた。酵素反応終了後、酵素を加熱失活させた後、濾過して酵素反応液を得た。酵素反応液を高速液体クロマトグラフィー(HPLC)により分析したところ、反応前の溶液中のヘスペリジンの72%がα-グルコシルヘスペリジンに変換しており、残り28%は未反応のままであった。酵素反応液に、α-L-ラムノシダーゼとしてヘスペリジナーゼ(商品名『可溶性ヘスペリジナーゼ<タナベ>2号』、田辺製薬製)を2質量部を添加し、pH4に調整し、55℃で24時間反応させた後、グルコアミラーゼ(商品名『グルコチーム』、ナガセケムテックス株式会社製)を1質量部加え、更に55℃で24時間反応させた。酵素反応終了後、得られた酵素反応液を加熱して酵素を加熱失活させ、中間極性多孔性吸着樹脂(商品名『アンバーライトXAD-7』、Rohm & Haas社製)を充填したカラムにかけ、カラムを水洗し、80v/v%エタノール水溶液にて樹脂吸着成分を溶出した。溶出液中のエタノールを除去した後、凍結乾燥し、α-グルコシルヘスペリジンを82.0重量%、7-O-β-グルコシルヘスペレチン8.0重量%、ヘスペリジンを1.0質量%、及びその他の成分を9.0重量%含む粉末状グリコシルヘスペレチン含有組成物を得た。
酵素反応液に対し、還元剤としてのメタ亜硫酸カリウムを0.001%添加した以外は実施例1と同様にして、淡黄色の粉末状グリコシルヘスペレチンを乾燥固形物当り原料のヘスペリジン質量に対して約69%の収率で得た。なお、本例で得られた粉末状グリコシルヘスペレチン含有組成物は、α-グルコシルヘスペリジン79.5%、ヘスペリジン13.8%、その他の成分を6.7%含有していた。
メタ亜硫酸カリウムを亜硫酸水素ナトリウムに代えた以外は実施例7と同様にして、淡黄色の粉末状グリコシルヘスペレチン含有組成物を、乾燥固形物当り、原料のヘスペリジン質量に対して約65%の収率で得た。なお、本例で得られた粉末状グリコシルヘスペレチン含有組成物は、α-グルコシルヘスペリジン77.2%、ヘスペリジン16.5%、その他の成分を6.3%含有していた。
酢酸カルシウム1水塩10質量部、L-乳酸マグネシウム3水塩50質量部、マルトース57質量部、実施例1で得た粉末状グリコシルヘスペレチン含有組成物150質量部及びエイコサペンタエン酸20%含有γ-シクロデキストリン包接化合物12質量部を均一に混合し、顆粒成形機にかけて顆粒とした後、常法に従って、ゼラチンカプセルに封入して、1カプセル当たり内容物を300mg含有するカプセル剤タイプの経口美容剤を得た。
実施例2乃至8で得たグリコシルヘスペレチン含有組成物のいずれかを10質量部、スクラロース0.003質量部、アスコルビン酸2-グルコシド(商品名『アスコフレッシュ』(登録商標)、株式会社林原販売)0.01質量部、及びデキストリン20質量部を撹拌混合し、スティック状の遮光・防湿性包装容器に0.5gずつ収容し、7種類の本発明の粉末状の経口美容剤を得た。
実施例10で得た7種類の粉末状の経口美容剤のいずれかを1質量部、アントシアニン0.001質量部、精製水30質量部、及び適量のpH調製剤を添加し撹拌し、pH7.0に調整し、精密濾過し、無菌容器に無菌的に充填して、5種類の本発明の液状の経口美容剤を得た。
実施例1で得た粉末状グリコシルヘスペレチン含有組成物1質量部を精製水50質量部に均一に溶解し、精密濾過し、無菌容器に充填し、複数種類の液状の経口美容剤を得た。
所定の還元剤を用いないで製造された、実施例1で得た粉末状グリコシルヘスペレチン含有組成物1質量部に対し、亜硫酸ナトリウム、次亜硫酸ナトリウム、ピロ亜硫酸カリウム、ピロ亜硫酸ナトリウム、及び二酸化イオウから選ばれる1種又は2種以上の還元剤を合計で0.0005質量部添加し、精製水50質量部に均一に溶解し、精密濾過し、無菌容器に充填し、複数種類の液状の経口美容剤を得た。
Claims (13)
- グリコシルヘスペレチンを有効成分とする、肌の黄くすみ、キメ、及び肌質を改善するための経口美容剤。
- グリコシルヘスペレチンが、ヘスペリジン、α-グリコシルヘスペリジン、及び7-O-β-グルコシルヘスペレチンから選ばれる1種又は2種以上であることを特徴とする、請求項1に記載の経口美容剤。
- α-グリコシルヘスペリジンが、α-グルコシルヘスペリジンであることを特徴とする、請求項1又は2に記載の経口美容剤。
- グリコシルヘスペレチンが、フルフラールを実質的に含まず、乾燥固形物当たり、グリコシルヘスペレチンを90質量%以上100質量%未満含有することを特徴とする、請求項1乃至3のいずれかに記載の経口美容剤。
- グリコシルヘスペレチンが、GC/MS分析法で測定されたフルフラール含量が、乾燥固形物当たり、200ppb未満であることを特徴とする、請求項1乃至4のいずれかに記載の経口美容剤。
- グリコシルヘスペレチンが、4-メトキシスチレンを実質的に含まないことを特徴とする、請求項1乃至5のいずれかに記載の経口美容剤。
- グリコシルヘスペレチンが、GC/MS分析法で測定された4-メトキシスチレン含量が、乾燥固形物当たり、30ppb未満であることを特徴とする、請求項6に記載の経口美容剤。
- 乾燥固形物当たりのα-グリコシルヘスペリジンの含量が、50質量%以上100質量%未満であることを特徴とする、請求項1乃至7のいずれかに記載の経口美容剤。
- グリコシルヘスペレチンが、1w/w%水溶液とし、これを密閉容器中で100℃で30分間加熱した後、27℃に調整し、幅1cmのセルに入れ、分光光度計により波長420nm及び波長720nmにおける吸光度を測定したときの両波長における吸光度の差が0.24未満であることを特徴とする、請求項1乃至8のいずれかに記載の経口美容剤。
- グリコシルヘスペレチンが、1w/w%水溶液とし、密閉容器中で100℃で30分間加熱した後、20℃としたときの電気伝導度が10μS/cm未満であることを特徴とする、請求項1乃至9のいずれかに記載の経口美容剤。
- グリコシルヘスペレチンが、高周波誘導結合プラズマ発光分光分析法で測定したときの組成物の乾燥固形物当たりのカルシウム、カリウム、マグネシウム、及びナトリウムの含量がそれぞれ、1ppm以下、0.1ppm以下、0.2ppm以下、及び0.4ppm以下であることを特徴とする、請求項1乃至10のいずれかに記載の経口美容剤。
- 錠剤、顆粒剤、粉剤、懸濁剤、ペースト状剤、ゼリー状剤、又は液剤の形態にあることを特徴とする請求項1乃至11のいずれかに記載の経口美容剤。
- グリコシルヘスペレチンを、ヘスペリジン換算で、一日1回当たり、10乃至3,000mg経口摂取することを可能とする単位投与形態にあることを特徴とする請求項1乃至12のいずれかに記載の経口美容剤。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016544235A JP6678928B2 (ja) | 2014-08-20 | 2015-08-19 | 経口美容剤 |
KR1020177007095A KR102554508B1 (ko) | 2014-08-20 | 2015-08-19 | 경구 미용제 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-167906 | 2014-08-20 | ||
JP2014167906 | 2014-08-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016027837A1 true WO2016027837A1 (ja) | 2016-02-25 |
Family
ID=55350779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/073272 WO2016027837A1 (ja) | 2014-08-20 | 2015-08-19 | 経口美容剤 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP6678928B2 (ja) |
KR (1) | KR102554508B1 (ja) |
TW (1) | TWI715536B (ja) |
WO (1) | WO2016027837A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017038951A1 (ja) * | 2015-09-02 | 2017-03-09 | 株式会社林原 | 黄ぐすみ低減用皮膚外用剤 |
EP3135682A4 (en) * | 2014-03-03 | 2017-08-16 | Hayashibara Co., Ltd. | Glucosyl hesperidin, method for manufacturing same, and application for same |
JP2022058792A (ja) * | 2016-05-16 | 2022-04-12 | グローバル バイオライフ インコーポレーテッド | 炎症関連疾患及び障害を治療するための求電子的に強化されたフェノール化合物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005015344A (ja) * | 2003-06-23 | 2005-01-20 | Nonogawa Shoji Kk | メイクアップ化粧料 |
JP2005253883A (ja) * | 2004-03-15 | 2005-09-22 | Kanebo Cosmetics Inc | 美白カウンセリングツールおよびそれを用いた美白カウンセリング方法 |
WO2009116450A1 (ja) * | 2008-03-17 | 2009-09-24 | 株式会社林原生物化学研究所 | エラスターゼ活性阻害剤 |
WO2013018779A1 (ja) * | 2011-08-01 | 2013-02-07 | 株式会社林原 | α-グルコシルヘスペリジンの結晶とその用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3060227B2 (ja) * | 1989-06-03 | 2000-07-10 | 株式会社林原生物化学研究所 | α―グリコシル ヘスペリジンとその製造方法並びに用途 |
JP3510861B2 (ja) | 2001-01-31 | 2004-03-29 | リバテープ製薬株式会社 | 美容食品 |
JP2002255827A (ja) | 2001-03-01 | 2002-09-11 | Shiseido Co Ltd | 皮膚外用剤 |
US20070160550A1 (en) * | 2004-01-24 | 2007-07-12 | Charles Nee Newsham Rebecca L | Skin lightening compositions |
JP2007186495A (ja) * | 2005-12-16 | 2007-07-26 | Ezaki Glico Co Ltd | 体調を改善する効果を持つ新規もろみ酢 |
JP2008099562A (ja) | 2006-10-17 | 2008-05-01 | Kao Corp | 美肌用経口組成物 |
JP2009007336A (ja) | 2007-05-25 | 2009-01-15 | Shiseido Co Ltd | α−グリコシルヘスペリジンを含有する経口投与・摂取用の、メラニン低下剤、皮膚明度低下抑制剤、皮膚粘弾性低下抑制剤、皮脂量低下抑制剤、SCF産生抑制剤、およびかゆみ抑制剤 |
WO2010119955A1 (ja) * | 2009-04-17 | 2010-10-21 | ロート製薬株式会社 | アドバンスド・グリケーション・エンド・プロダクツの蓄積による肌の老化の予防、抑制、又は改善剤 |
KR101619342B1 (ko) * | 2010-02-26 | 2016-05-11 | (주)아모레퍼시픽 | 피부 색상 측정 시스템 및 방법 |
-
2015
- 2015-08-19 KR KR1020177007095A patent/KR102554508B1/ko active IP Right Grant
- 2015-08-19 JP JP2016544235A patent/JP6678928B2/ja active Active
- 2015-08-19 WO PCT/JP2015/073272 patent/WO2016027837A1/ja active Application Filing
- 2015-08-20 TW TW104127189A patent/TWI715536B/zh active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005015344A (ja) * | 2003-06-23 | 2005-01-20 | Nonogawa Shoji Kk | メイクアップ化粧料 |
JP2005253883A (ja) * | 2004-03-15 | 2005-09-22 | Kanebo Cosmetics Inc | 美白カウンセリングツールおよびそれを用いた美白カウンセリング方法 |
WO2009116450A1 (ja) * | 2008-03-17 | 2009-09-24 | 株式会社林原生物化学研究所 | エラスターゼ活性阻害剤 |
WO2013018779A1 (ja) * | 2011-08-01 | 2013-02-07 | 株式会社林原 | α-グルコシルヘスペリジンの結晶とその用途 |
Non-Patent Citations (1)
Title |
---|
FRAGRANCE JOURNAL, vol. 30, no. 12, 15 December 2002 (2002-12-15), pages 70, 71 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3135682A4 (en) * | 2014-03-03 | 2017-08-16 | Hayashibara Co., Ltd. | Glucosyl hesperidin, method for manufacturing same, and application for same |
US10703773B2 (en) | 2014-03-03 | 2020-07-07 | Hayashibara Co. Ltd. | Glycosyl hesperetin and process for producing the same and uses thereof |
EP3935960A1 (en) * | 2014-03-03 | 2022-01-12 | Hayashibara Co., Ltd. | Glycosyl hesperetin and process for producing the same and uses thereof |
US11453694B2 (en) | 2014-03-03 | 2022-09-27 | Hayashibara Co. Ltd. | Glycosyl hesperetin and process for producing the same and uses thereof |
WO2017038951A1 (ja) * | 2015-09-02 | 2017-03-09 | 株式会社林原 | 黄ぐすみ低減用皮膚外用剤 |
EP3342396A4 (en) * | 2015-09-02 | 2019-06-05 | Hayashibara Co., Ltd. | EXTERNAL DERMATOLOGICAL PREPARATION TO REDUCE SKIN JAUNDER |
US10568827B2 (en) | 2015-09-02 | 2020-02-25 | Hayashibara Co., Ltd. | External dermal agent for reducing yellowish dullness |
JP2022058792A (ja) * | 2016-05-16 | 2022-04-12 | グローバル バイオライフ インコーポレーテッド | 炎症関連疾患及び障害を治療するための求電子的に強化されたフェノール化合物 |
JP7376624B2 (ja) | 2016-05-16 | 2023-11-08 | グローバル バイオライフ インコーポレーテッド | 炎症関連疾患及び障害を治療するための求電子的に強化されたフェノール化合物 |
Also Published As
Publication number | Publication date |
---|---|
KR102554508B1 (ko) | 2023-07-13 |
TWI715536B (zh) | 2021-01-11 |
JP6678928B2 (ja) | 2020-04-15 |
KR20170042707A (ko) | 2017-04-19 |
JPWO2016027837A1 (ja) | 2017-07-20 |
TW201618792A (zh) | 2016-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11453694B2 (en) | Glycosyl hesperetin and process for producing the same and uses thereof | |
JP7049496B2 (ja) | 黄ぐすみ低減用皮膚外用剤 | |
KR0165956B1 (ko) | 알파-글리코실 루틴을 함유시킨 음식물의 제조방법 | |
TW200902077A (en) | Whitening agent comprising equol or its saccharide derivative as an effective ingredient | |
US20110207697A1 (en) | Xanthohumol compositions and methods for treating skin diseases or disorders | |
WO2016027837A1 (ja) | 経口美容剤 | |
JP2002199896A (ja) | 3”−α−モノグルコシルナリンジン含有組成物、その製造方法およびその利用方法 | |
KR102128168B1 (ko) | 표고버섯 추출물 및 고로쇠 잎 추출물을 포함하는 항노화 활성을 갖는 조성물 | |
JP4414711B2 (ja) | 活性酸素消去剤及びその製造方法 | |
EP3903591A1 (en) | Heat stress alleviation agent | |
See et al. | A comprehensive review and recent advances of vitamin C: Overview, functions, sources, applications, market survey and processes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15833083 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016544235 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20177007095 Country of ref document: KR Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15833083 Country of ref document: EP Kind code of ref document: A1 |